Patent Publication Number: US-11638706-B2

Title: Methods for treating Huntington&#39;s disease

Description:
CROSS-REFERENCE TO RELATED APPLICATIONS 
     This application is a Continuation of U.S. patent application Ser. No. 16/710,515, filed Dec. 11, 2019, now U.S. Pat. No. 10,881,658, issued Jan. 5, 2021, which in turn is a Divisional of U.S. patent application Ser. No. 15/781,303, filed Jun. 4, 2018, now U.S. Pat. No. 10,874,672, issued Dec. 29, 2020, which is the U.S. National Stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2016/066042, filed Dec. 11, 2016, which in turn claims priority to U.S. Provisional Application No. 62/265,652, filed Dec. 10, 2015, the entire contents of which are incorporated by reference herein. 
    
    
     FIELD OF THE INVENTION 
     The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington&#39;s disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington&#39;s disease. 
     BACKGROUND 
     Huntington&#39;s disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent. The disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the “mutant” huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a “CAG repeat” sequence. There are no current small molecule therapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide small molecule compounds for treating or ameliorating HD. 
     All other documents referred to herein are incorporated by reference into the present application as though fully set forth herein. 
     SUMMARY 
     The present description relates to methods for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): 
                         
wherein W, X, A and B are as defined herein, or forms and compositions thereof.
 
     In particular, the present description relates to a use of a compound of Formula (I) or a form or composition thereof in a method for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof, to the subject. 
     The present description further relates to the use of a compound of Formula (I) or a form thereof in combination with agents having additive or synergistic activity, thus providing a combination product for the treatment of HD. 
    
    
     DETAILED DESCRIPTION 
     The present description relates to a method or use of a compound for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): 
                         
or a form thereof, wherein
     W is CH═CH or S;   X is CH 2 , CH(C 1-4 alkyl), C(C 1-4 alkyl) 2 , CH═CH, O, NRs, or a bond;   A is aryl, heteroaryl, heterocyclyl, or C 9-10 cycloalkyl,   wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from R 1 ,   wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S, or N atom, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 1 ,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 , and   wherein C 9-10 cycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 ;   B is heterocyclyl,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 4 ;   R 1  is halogen, hydroxyl, cyano, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, (C 1-4 alkyl) 2 -amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, heterocyclyl-C 1-4 alkoxy, phenyl, or phenyl-C 1-4 alkoxy,   wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms such as an O, S, or N atom,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and   wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ;   R 2  is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, hydroxyl-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 2-4 alkenyl, C 3-7 cycloalkyl, or heterocyclyl-C 1-4 alkyl,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and   wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ;   R 3  is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, (C 1-4 alkyl) 2 -amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, phenyl, or phenyl-C 1-4 alkoxy;   R 4  is independently selected from halogen, C 1-4 alkyl, hydroxyl-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino or hydroxyl-C 1-4 alkyl-amino; and   R 5  is hydrogen, C 1-4 alkyl, or hydroxyl-C 1-4 alkyl;   wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.   

     An embodiment of the present description further relates to a method or use of a compound for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) selected from a compound of Formula (Ia) and Formula (Ib): 
                         
or a form thereof, wherein
     X is CH 2 , CH(C 1-4 alkyl), C(C 1-4 alkyl) 2 , CH═CH, O, NRs, or a bond;   A is aryl, heteroaryl, heterocyclyl, or C 9-10 cycloalkyl,   wherein aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from R 1 ,   wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S, or N atom, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 1 ,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 , and   wherein C 9-10 cycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 ;   B is heterocyclyl,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 4 ;   R 1  is halogen, hydroxyl, cyano, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, heterocyclyl-C 1-4 alkoxy, phenyl, or phenyl-C 1-4 alkoxy,   wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms such as an O, S, or N atom,   wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and   wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ;   R 2  is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, amino-carbonyl, hydroxyl-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 2-4 alkenyl, C 3-7 cycloalkyl, or heterocyclyl-C 1-4 alkyl;   R 3  is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, phenyl, or phenyl-C 1-4 alkoxy;   R 4  is independently selected from halogen, C 1-4 alkyl, hydroxyl-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino or hydroxyl-C 1-4 alkyl-amino; and   R 5  is hydrogen, C 1-4 alkyl, or hydroxyl-C 1-4 alkyl;   wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.   

     Another embodiment of the present description further relates to methods for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) selected from a compound of Formula (Ia) and Formula (Ib): 
                         
or a form thereof, wherein
     X is O, NH, N(CH 3 ) or a bond;   A is aryl, heteroaryl or heterocyclyl,   wherein aryl is selected from the group consisting of   

     
       
         
         
             
             
         
       
         
         wherein heteroaryl is selected from the group consisting of 
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         wherein heterocyclyl is selected from the group consisting of 
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         B is heterocyclyl selected from the group consisting of 
       
    
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
         
         R 1a , R 1b  and R 1c  are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, (C 1-4 alkyl) 2 -amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, heterocyclyl-C 1-4 alkoxy, phenyl, or phenyl-C 1-4 alkoxy, 
         wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms such as an O, S, or N atom, 
         wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and 
         wherein each instance of phenyl, heteroaryl or heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ; 
         R 2a , R 2b  and R 2c  are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, oxo, hydroxyl-imino, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, hydroxyl-C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 2-4 alkenyl, C 3-7 cycloalkyl, or heterocyclyl-C 1-4 alkyl, 
         wherein heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and 
         wherein each instance of heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ; 
         R 3  is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino, amino-C 1-4 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-C 1-4 alkyl, amino-carbonyl, C 1-4 alkyl-amino-carbonyl, (C 1-4 alkyl) 2 -amino-carbonyl, C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, (C 1-4 alkyl) 2 -amino-carbonyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl-amino, C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, hydroxyl-C 1-4 alkyl, C 1-4 alkyl-carbonyl, C 1-4 alkoxy, halo-C 1-4 alkoxy, amino-C 1-4 alkoxy, hydroxyl-C 1-4 alkoxy, C 1-4 alkyl-C 1-4 alkoxy, C 1-4 alkyl-amino-C 1-4 alkoxy, (C 1-4 alkyl) 2 -amino-C 1-4 alkoxy, C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy, C 1-4 alkoxy-C 1-4 alkoxy, C 1-4 alkoxy-carbonyl, C 1-4 alkoxy-carbonyl-amino, C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy, C 2-4 alkenyl, C 2-4 alkenyl-amino-carbonyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkoxy, C 3-7 cycloalkenyl, heteroaryl, heteroaryl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl, heteroaryl-C 1-4 alkyl-carbonyl-amino, heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl, heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl, heterocyclyl, heterocyclyl-C 1-4 alkyl, phenyl, or phenyl-C 1-4 alkoxy; and 
         R 4a , R 4b , R 4c , R 4d , R 4e , R 4f  and R 4g  are independently selected from halogen, C 1-4 alkyl, hydroxyl-C 1-4 alkyl, amino, C 1-4 alkyl-amino, (C 1-4 alkyl) 2 -amino or hydroxyl-C 1-4 alkyl-amino; 
         wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. 
       
    
     Another aspect of the present description relates to a compound of Formula (I) selected from a compound of Formula (Ia11), Formula (Ia15), Formula (Ia18) or Formula (Ib1): 
                         
or a form thereof, wherein (when present),
     X is selected from O, NR 5 , or a bond;   A is selected from phenyl, thiophenyl, indazolyl, pyridinyl, pyrimidinyl or phenoxy,   wherein phenyl and phenoxy are each optionally substituted with 1, 2 or 3 substituents each selected from R 1a ,   wherein thiophenyl, indazolyl, pyridinyl, pyrimidinyl are each optionally substituted with 1 or 2 substituents each selected from R 1a ,   B is selected from 1H-pyrazolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, 2,6-diazaspiro[3.4]octyl or 2,7-diazaspiro[3.5]nonyl, each optionally substituted with 1 or 2 substituents each selected from R 4a ;   R 1a  is selected from halogen, hydroxyl, C 1-4 alkyl, halo-C 1-4 alkyl, amino, C 1-4 alkoxy, or heteroaryl,   wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms such as an O, S, or N atom, optionally substituted with 1 or 2 substituents each selected from R3a;   R 3a  is selected from nitro or C 1-4 alkyl; and,   R 4a  is C 1-4 alkyl;   R 5a  is hydrogen, C 1-4 alkyl, or hydroxyl-C 1-4 alkyl;   wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.   

     Another aspect of the present description relates to a compound of Formula (I) selected from a compound of Formula (Ia11), Formula (Ia15), Formula (Ia18) or Formula (Ib1): 
     or a form thereof, wherein (when present), 
     
         
         R 1a  is selected from fluoro, chloro, hydroxyl, methyl, difluoromethyl, amino, methoxy or 1H-pyrazolyl or 1H-imidazol-1-yl, 
         wherein 1H-pyrazolyl is optionally substituted with 1 or 2 substituents each selected from R 3a ; 
         R 3a  is selected from nitro or methyl or amino; and, 
         R 4a  is methyl or ethyl; 
         R 5a  is hydrogen or methyl; 
         wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. 
       
    
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia1) or a form thereof, wherein substituents R 1a , R 1b , and X, when present, are indicated in the table below with multiple substituents separated by a comma; and, “--” indicates that one or more R 1a , R 1b , and X substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 X 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 1 
                 — 
                 — 
                 NH 
               
               
                 8 
                 2-OH 
                 — 
                 N(CH 3 ) 
               
               
                 40 
                 1-CH 2 CH═CH 2 , 
                 — 
                 N(CH 3 ) 
               
               
                   
                 2-OH 
                   
                   
               
               
                 106 
                 1-Br, 
                 7-OH 
                 N(CH 3 ) 
               
               
                   
                 2-OH 
                   
                   
               
               
                 107 
                 1-Cl, 
                 7-OH 
                 N(CH 3 ) 
               
               
                   
                 2-OH 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia2) or a form thereof, wherein substituents R 1a , R 1b , and R 4a , when present, are indicated in the table below with multiple substituents separated by a comma; and, “--” indicates that one or more R 1a , R 1b , and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 13 
                 — 
                 — 
                 — 
               
               
                 207 
                 — 
                 7-OH 
                 — 
               
               
                 208 
                 — 
                 7-OH 
                 CH 3   
               
               
                 210 
                 2-CH 3   
                 7-OH 
                 — 
               
               
                 222 
                 3-Cl 
                 7-OH 
                 — 
               
               
                 223 
                 3-Br 
                 7-OH 
                 — 
               
               
                 224 
                 3-CN 
                 7-OH 
                 — 
               
               
                 225 
                 3-(1-CH 3 -1H-imidazol-4-yl) 
                 7-OH 
                 — 
               
               
                 226 
                 3-(1H-imidazol-1-yl) 
                 7-OH 
                 — 
               
               
                 227 
                 3-OH 
                 7-OH 
                 — 
               
               
                 228 
                 3-CH 2 CH 3   
                 7-OH 
                 — 
               
               
                 229 
                 3-CH(CH 3 ) 2   
                 7-OH 
                 — 
               
               
                 232 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-OCH 3 , 
                   
                   
               
               
                 233 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(pyrrolidin-1-yl) 
                   
                   
               
               
                 234 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(morpholin-4-yl) 
                   
                   
               
               
                 235 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-N(CH 3 ) 2   
                   
                   
               
               
                 236 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-OCH 2 CH 3   
                   
                   
               
               
                 237 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(1-CH 3 -1H-pyrazol-4-yl) 
                   
                   
               
               
                 240 
                 3-(tetrahydro-2H-pyran-4-yl) 
                 7-OH 
                 — 
               
               
                 249 
                 4-OCH 3   
                 7-OH 
                 — 
               
               
                 250 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(azetidin-1-yl) 
                   
                   
               
               
                 251 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-CN 
                   
                   
               
               
                 252 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-cyclopropyl 
                   
                   
               
               
                 253 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(3,6-dihydro-2H-pyran-4-yl) 
                   
                   
               
               
                 254 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(tetrahydro-2H-pyran-4-yl) 
                   
                   
               
               
                 255 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-(oxetan-3-yl) 
                   
                   
               
               
                 256 
                 4-N(CH 3 ) 2   
                 7-OH 
                 — 
               
               
                 262 
                 2-CN 
                 7-OH 
                 — 
               
               
                 265 
                 2-C(O)NH 2   
                 7-OH 
                 — 
               
               
                 293 
                 3-Cl 
                 7-OH 
                 — 
               
               
                 294 
                 3-CH(CH 3 ) 2   
                 7-OH 
                 — 
               
               
                 296 
                 2-CH 3 , 
                 7-OH 
                 — 
               
               
                   
                 4-Cl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia3) or a form thereof, wherein substituents R 1a , R 1b  and X, when present, are indicated in the table below with multiple substituents separated by a comma; and, “--” indicates that one or more R 1a , R 1b  and X substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 X 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 11 
                 — 
                 — 
                 O 
               
               
                 15 
                 — 
                 — 
                 N(CH 3 ) 
               
               
                 218 
                 — 
                 7-OH 
                 N(CH 3 ) 
               
               
                 261 
                 1-CN 
                 7-OH 
                 N(CH 3 ) 
               
               
                 272 
                 1-CH 3   
                 7-OH 
                 N(CH 3 ) 
               
               
                 275 
                 1-CN, 
                 7-OH 
                 N(CH 3 ) 
               
               
                   
                 3-CH 3   
                   
                   
               
               
                 292 
                 3-(OCH 2 -phenyl) 
                 — 
                 N(CH 3 ) 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia4) or a form thereof, wherein substituents X, R 1a , R 1b  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a , R 1b  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 X 
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 10 
                 — 
                 — 
                 O 
                 — 
               
               
                 14 
                 — 
                 — 
                 N(CH 3 ) 
                 — 
               
               
                 159 
                 1-(OCH 2 -phenyl) 
                 — 
                 N(CH 3 ) 
                 — 
               
               
                 211 
                 — 
                 6-OH 
                 N(CH 3 ) 
                 CH 3   
               
               
                 212 
                 — 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 213 
                 — 
                 6-OH 
                 O 
                 — 
               
               
                 215 
                 1-cyclopropyl 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 216 
                 1-OH 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 217 
                 1-CN 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 264 
                 1-C(O)NH 2   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 273 
                 1-CH3 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 274 
                 1,3-(CH 3 ) 2   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 276 
                 1-NH 2   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 283 
                 1-OCH 2 CH 3   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 284 
                 1-OH 
                 6-OH 
                 O 
                 — 
               
               
                 285 
                 3-phenyl 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 286 
                 3-CH 3   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 287 
                 3-cyclopropyl 
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 288 
                 3-CH(CH 3 ) 2   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 289 
                 3-(CH 2 ) 2 CH 3   
                 6-OH 
                 N(CH 3 ) 
                 — 
               
               
                 290 
                 3-CH(CH 3 ) 2   
                 6-OH 
                 O 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia5) or a form thereof, wherein substituents R 1a  and R 1b , when present, are indicated in the table below with multiple substituents separated by a comma; and, “--” indicates that one or more R 1a  and R 1b  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 12 
                 — 
                 — 
               
               
                 220 
                 — 
                 6-OH 
               
               
                 221 
                 2-CH 3   
                 6-OH 
               
               
                 238 
                 4-OCH 3   
                 6-OH 
               
               
                 241 
                 3-Cl 
                 6-OH 
               
               
                 242 
                 3-Br 
                 6-OH 
               
               
                 243 
                 3-CH 3   
                 6-OH 
               
               
                 244 
                 3-CH 3   
                 5-Br, 
               
               
                   
                   
                 6-OH 
               
               
                 263 
                 2-CN 
                 6-OH 
               
               
                 266 
                 2-C(O)NH 2   
                 6-OH 
               
               
                 267 
                 2-CO 2 CH 3   
                 6-OH 
               
               
                 297 
                 4-Cl 
                 6-OH 
               
               
                 300 
                 — 
                 6-OH 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia6) or a form thereof, wherein substituents R 1a , when present, are indicated in the table below; and, “--” indicates that one or more R 1a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 239 
                 — 
               
               
                 246 
                 2,3-(CH 3 ) 2   
               
               
                 247 
                 2-CH 3   
               
               
                 248 
                 3-CH 3   
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia7) or a form thereof, wherein substituents R 1a , when present, are indicated in the table below; and, “--” indicates that one or more R 1a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 258 
                 — 
               
               
                 260 
                 2-CH 3   
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia8) or a form thereof, wherein substituents R 1a  and B, when present, are indicated in the table below; and, “--” indicates that one or more R 1a  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 209 
                 — 
                 6-((3aR,6aS)-5-CH 3 -hexahydropyrrolo[3,4- 
               
               
                   
                   
                 c]pyrrol-2(1H)-yl) 
               
               
                 269 
                 2-CN 
                 piperazin-1-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia9) or a form thereof, wherein substituents R 1a  and B, when present, are indicated in the table below; and, “--” indicates that one or more R 1a  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 214 
                 — 
                 6-((3aR,6aS)-5-CH 3 -hexahydropyrrolo[3,4- 
               
               
                   
                   
                 c]pyrrol-2(1H)-yl) 
               
               
                 270 
                 — 
                 piperazin-1-yl 
               
               
                 291 
                 3-CH 3   
                 piperazin-1-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia10) or a form thereof, wherein substituents R 1a  and B, when present, are indicated in the table below; and, “--” indicates that one or more R 1a  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 268 
                 2-CN 
                 piperazin-1-yl 
               
               
                 271 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia11) or a form thereof, wherein substituents A, X and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more A, X and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 A 
                 X 
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 2 
                 benzo[b]thiophen-2-yl 
                 N(CH 3 ) 
                 — 
               
               
                 4 
                 5-CN-benzo[b]thiophen-2-yl 
                 N(CH 3 ) 
                 — 
               
               
                 5 
                 quinolin-3-yl 
                 NH 
                 — 
               
               
                 6 
                 benzo[b]thiophen-2-yl 
                 O 
                 — 
               
               
                 9 
                 benzo[b]thiophen-2-yl 
                 NH 
                 — 
               
               
                 16 
                 imidazo[1,2-a]pyridin-6-yl 
                 N(CH 3 ) 
                 — 
               
               
                 17 
                 6-phenyl-pyridin-3-yl 
                 N(CH 3 ) 
                 — 
               
               
                 18 
                 6-(1H-pyrrol-1-yl)-pyridin-3-yl 
                 N(CH 3 ) 
                 — 
               
               
                 19 
                 6-(1H-pyrazol-1-yl)-pyridin-3-yl 
                 N(CH 3 ) 
                 — 
               
               
                 20 
                 quinoxalin-2-yl 
                 N(CH 3 ) 
                 — 
               
               
                 21 
                 quinolin-3-yl 
                 N(CH 3 ) 
                 — 
               
               
                 22 
                 phthalazin-6-yl 
                 N(CH 3 ) 
                 — 
               
               
                 23 
                 benzo[c][1,2,5]oxadiazol-5-yl 
                 NH 
                 — 
               
               
                 24 
                 benzo[d]thiazol-5-yl 
                 NH 
                 — 
               
               
                 25 
                 2-CH 3 -benzo[d]oxazol-6-yl 
                 NH 
                 — 
               
               
                 30 
                 2-(4-CN-phenol) 
                 N(CH 3 ) 
                 — 
               
               
                 32 
                 2-(4-CF 3 -phenol) 
                 N(CH 3 ) 
                 — 
               
               
                 33 
                 6-(2-F-phenol) 
                 N(CH 3 ) 
                 — 
               
               
                 34 
                 2-[3,5-(OCH 3 ) 2 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 35 
                 2-[4,5-(OCH 3 ) 2 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 37 
                 2-(4,5-F 2 -phenol) 
                 N(CH 3 ) 
                 — 
               
               
                 41 
                 benzo[b]thiophen-2-yl 
                 NH 
                 CH 3   
               
               
                 53 
                 2-[4-(1H-pyrazol-1-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 115 
                 2-[3-OH-5-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 116 
                 2-[3-OCH 3 -5-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 117 
                 2-[5-(1H-pyrazol-4-yl)-3-OCF 3 -phenol] 
                 NH 
                 — 
               
               
                 118 
                 2-[5-(1-CH 3 -1H-pyrazol-4-yl)-3-OCF 3 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 119 
                 2-[5-(1H-pyrazol-4-yl)-3-OCF 3 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 120 
                 2-[5-(1-CH 3 -pyridin-2(1H)-one)-3-OCF 3 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 121 
                 2-[3-OCH 3 -5-(1-CH 3 -1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 122 
                 2-[3-OCH 3 -5-(5,6,7,8-tetrahydroimidazo-[1,2- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 a]pyridin-3-yl)-phenol] 
                   
                   
               
               
                 123 
                 2-[3-OCH 3 -5-(pyridin-3-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 124 
                 2-[3-OCH 3 -5-(1-cyclopentyl-1H-pyrazol-4-yl)- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 phenol] 
                   
                   
               
               
                 125 
                 2-[5-(3-OCH 3 -phenyl)-3-OCH 3 -phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 126 
                 2-[3-benzyloxy-5-(5-CH 3 -oxazol-2-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 127 
                 2-[3-OCH 2 CH 3 -5-(5-CH 3 -oxazol-2-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 128 
                 2-[3-(OCH 2 -cyclopropyl)-5-(5-CH 3 -oxazol-2-yl)- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 phenol] 
                   
                   
               
               
                 129 
                 5-(2-CH 3 -1H-benzo[d]imidazol-6-ol) 
                 N(CH 3 ) 
                 — 
               
               
                 134 
                 2-[4-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 135 
                 2-[4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 yl)-phenol] 
                   
                   
               
               
                 136 
                 2-[4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 yl)-phenol] 
                   
                   
               
               
                 137 
                 2-[4-(1H-indol-2-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 138 
                 2-[4-(cyclopent-1-en-1-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 139 
                 2-[4-(1H-pyrazol-3-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 140 
                 2-[4-(2-OH-pyridin-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 141 
                 2[4-(1-CH 3 -pyridin-2(1H)-one)-phenol] 
                 O 
                 — 
               
               
                 142 
                 2-[4-(2-OH-pyridin-4-yl)-phenol] 
                 O 
                 — 
               
               
                 144 
                 2-[4-Cl-5-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 145 
                 2-[4-F-5-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 146 
                 2-[5-F-4-(1H-imidazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 147 
                 2-[5-F-4-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 148 
                 2-[5-F-(1H-pyrazol-5-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 149 
                 6-OH-1-oxo-2,3-dihydro-1H-inden-5-yl 
                 N(CH 3 ) 
                 — 
               
               
                 150 
                 6-(1,4-dihydroindeno[1,2-c]-1H-pyrazol-7-ol) 
                 N(CH 3 ) 
                 — 
               
               
                 151 
                 6-OH-1-OH-imino-2,3-dihydro-1H-inden-5-yl 
                 N(CH 3 ) 
                 — 
               
               
                 152 
                 6-OH-1-OH-2,3-dihydro-1H-inden-5-yl 
                 N(CH 3 ) 
                 — 
               
               
                 153 
                 6-(2-NH 2 -8H-indeno[1,2-d]thiazol-5-ol) 
                 N(CH 3 ) 
                 — 
               
               
                 154 
                 9-(5,6-dihydroimidazo[5,1-a]isoquinolin-8-ol) 
                 N(CH 3 ) 
                 — 
               
               
                 155 
                 2-{4-[C(O)NHCH 2 -(1-CH 3 -1H-pyrazol-4-yl)]- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 phenol} 
                   
                   
               
               
                 156 
                 2-[4-(4-CH 2 OH-1H-pyrazol-1-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 158 
                 3-(OCH 2 -phenyl)-isoquinolin-6-yl 
                 N(CH 3 ) 
                 — 
               
               
                 160 
                 2-[3-F-5-(2-OCH 3 -pyridin-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 161 
                 4-[1-(4-pyridin-2(1H)-one)-3-F-5-OH-phenyl] 
                 N(CH 3 ) 
                 — 
               
               
                 162 
                 4-{1-[4-(1-CH 3 -pyridin-2(1H)-one)]-3-F-5-OH- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 phenyl} 
                   
                   
               
               
                 163 
                 4-{1-[5-(1-CH 3 -pyridin-2(1H)-one)]-3-F-5-OH- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 phenyl} 
                   
                   
               
               
                 164 
                 2-[3-F-5-(1H-pyrazol-4-yl)-phenol] 
                 O 
                 — 
               
               
                 165 
                 2-(5-Cl-3-F-phenol) 
                 N(CH 3 ) 
                 — 
               
               
                 166 
                 2-[3-F-5-(1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 167 
                 2-[3-F-5-(1-CH 3 -1H-pyrazol-4-yl)-phenol] 
                 N(CH 3 ) 
                 — 
               
               
                 219 
                 8-(quinolin-7-ol) 
                 N(CH 3 ) 
                 — 
               
               
                 230 
                 6-(7-OH-quinolin-2(1H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 231 
                 6-(7-OH-1-CH 3 -quinolin-2(1H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 245 
                 7-(6-OH-1-CH 3 -quinolin-4(1H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 257 
                 6-(7-OH-quinazolin-4(1H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 259 
                 6-(7-OH-1-CH 3 -3,4-dihydroquinolin-2(1H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 277 
                 7-OH-1,3-(CH 3 ) 2 -quinazolin-6-yl-2,4(1H,3H)- 
                 N(CH 3 ) 
                 — 
               
               
                   
                 dione 
                   
                   
               
               
                 278 
                 6-OH-benzo[d]oxazol-5-yl-2(3H)-one 
                 N(CH 3 ) 
                 — 
               
               
                 279 
                 2-CH 3 -6-OH-2H-indazol-5-yl 
                 N(CH 3 ) 
                 — 
               
               
                 280 
                 1-CH 3 -6-OH-1H-indazol-5-yl 
                 N(CH 3 ) 
                 — 
               
               
                 281 
                 7-(6-OH-2-CH 3 -isoquinolin-1(2H)-one) 
                 N(CH 3 ) 
                 — 
               
               
                 282 
                 7-(6-OH-2-CH 2 CH 3 -isoquinolin-1(2H)-one) 
                 O 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the present description includes a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia11) or a form thereof, wherein substituents A, X and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more A, X and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 A 
                 X 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 420 
                 2-OCH 3 -4-(4-NO 2 -1H-pyrazol-1-yl)phenyl 
                 N(CH 3 ) 
               
               
                 428 
                 2,5-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 430 
                 2,3-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 431 
                 2,5-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 434 
                 2-OCH 3 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 435 
                 4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 437 
                 2-F-4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 438 
                 4-(1-CH 3 -1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 440 
                 2-F-4-OH-phenyl 
                 N(CH 3 ) 
               
               
                 442 
                 2-CH 3 -2H-indazol-5-yl 
                 N(CH 3 ) 
               
               
                 443 
                 2-CH 3 -2H-indazol-5-yl 
                 O 
               
               
                 444 
                 4-Cl-2-OCH 3 -phenyl 
                 O 
               
               
                 445 
                 2-CH 3 -pyrazolo[1,5-a]pyridin-3-yl 
                 N(CH 3 ) 
               
               
                 446 
                 imidazo[1,2-a]pyridin-6-yl 
                 O 
               
               
                 447 
                 2-OCH 3 -4-(1H-pyrazol-1-yl)phenyl 
                 O 
               
               
                 448 
                 5-(1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 449 
                 5-(1-CH 3 -1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 450 
                 4-(1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 451 
                 2-OH-4-[3,5-(CH 3 ) 2 -1H-pyrazol-4-yl]phenyl 
                 O 
               
               
                 452 
                 2-F-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 453 
                 2-OCH 3 -4-OH-phenyl 
                 O 
               
               
                 454 
                 2-OCH 3 -4-(4-NO 2 -1H-pyrazol-1-yl)phenyl 
                 O 
               
               
                 455 
                 2,4-(OH) 2 -phenyl 
                 O 
               
               
                 456 
                 2-Cl-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 457 
                 5-amino-2-(lH-pyrazol-4-yl)pyrimidin-4-yl 
                 O 
               
               
                 458 
                 2,6-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 464 
                 2-(CHF 2 )-4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 465 
                 2-(CHF 2 )-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia11) or a form thereof, wherein substituents A, X and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more A, X and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 A 
                 X 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 420 
                 2-OCH 3 -4-(4-NO 2 -1H-pyrazol-1-yl)phenyl 
                 N(CH 3 ) 
               
               
                 428 
                 2,5-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 430 
                 2,3-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 431 
                 2,5-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 434 
                 2-OCH 3 -4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 435 
                 4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 437 
                 2-F-4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 438 
                 4-(1-CH 3 -1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 440 
                 2-F-4-OH-phenyl 
                 N(CH 3 ) 
               
               
                 442 
                 2-CH 3 -2H-indazol-5-yl 
                 N(CH 3 ) 
               
               
                 443 
                 2-CH 3 -2H-indazol-5-yl 
                 O 
               
               
                 444 
                 4-Cl-2-OCH 3 -phenyl 
                 O 
               
               
                 445 
                 2-CH 3 -pyrazolo[1,5-a]pyridin-3-yl 
                 N(CH 3 ) 
               
               
                 446 
                 imidazo[1,2-a]pyridin-6-yl 
                 O 
               
               
                 447 
                 2-OCH 3 -4-(1H-pyrazol-1-yl)phenyl 
                 O 
               
               
                 448 
                 5-(1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 449 
                 5-(1-CH 3 -1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 450 
                 4-(1H-pyrazol-4-yl)thiophen-2-yl 
                 O 
               
               
                 451 
                 2-OH-4-[3,5-(CH 3 ) 2 -1H-pyrazol-4-yl]phenyl 
                 O 
               
               
                 452 
                 2-F-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 453 
                 2-OCH 3 -4-OH-phenyl 
                 O 
               
               
                 454 
                 2-OCH 3 -4-(4-NO 2 -1H-pyrazol-1-yl)phenyl 
                 O 
               
               
                 455 
                 2,4-(OH) 2 -phenyl 
                 O 
               
               
                 456 
                 2-Cl-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                 457 
                 5-amino-2-(1H-pyrazol-4-yl)pyrimidin-4-yl 
                 O 
               
               
                 458 
                 2,6-F 2 -4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 464 
                 2-(CHF 2 )-4-(1H-pyrazol-4-yl)phenyl 
                 O 
               
               
                 465 
                 2-(CHF 2 )-4-(1H-pyrazol-4-yl)phenyl 
                 N(CH 3 ) 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia12) or a form thereof, wherein substituents X, R 1a  and B, when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 X 
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 66 
                 H 
                 NH 
                 azetidin-3-yl 
               
               
                 82 
                 OH 
                 — 
                 piperazin-1-yl 
               
               
                 85 
                 H 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 86 
                 OH 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 87 
                 OH 
                 — 
                 2,2,6,6-tetramethyl-(1,2,3,6- 
               
               
                   
                   
                   
                 tetrahydropyridin-4-yl) 
               
               
                 88 
                 OH 
                 — 
                 1-CH 3 -(1,2,3,6- 
               
               
                   
                   
                   
                 tetrahydropyridin-4-yl) 
               
               
                 89 
                 OH 
                 — 
                 piperidin-4-yl 
               
               
                 99 
                 H 
                 CH 2   
                 piperidin-4-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia13) or a form thereof, wherein substituents X, R 1a  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 R 1a   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 26 
                 N(CH 3 ) 
                 H 
                 — 
               
               
                 28 
                 NH 
                 H 
                 — 
               
               
                 31 
                 O 
                 H 
                 — 
               
               
                 90 
                 O 
                 OH 
                 — 
               
               
                 91 
                 N(CH 3 ) 
                 OH 
                 — 
               
               
                 92 
                 NH 
                 OH 
                 — 
               
               
                 93 
                 N(CH 3 ) 
                 O(CH 2 ) 3 NHCO 2 C(CH 3 ) 3   
                 — 
               
               
                 94 
                 N(CH 3 ) 
                 O(CH 2 ) 3 NH 2   
                 — 
               
               
                 95 
                 N(CH 3 ) 
                 O(CH 2 ) 3 NHCO 2 CH 3   
                 — 
               
               
                 96 
                 N(CH 3 ) 
                 O(CH 2 ) 3 OH 
                 — 
               
               
                 97 
                 N(CH 3 ) 
                 O(CH 2 ) 3 OCH 3   
                 — 
               
               
                 98 
                 O 
                 O(CH 2 ) 3 -morpholin-4-yl 
                 — 
               
               
                 103 
                 N(CH 3 ) 
                 CN 
                 — 
               
               
                 104 
                 N(CH 3 ) 
                 CH 2 -1-piperidinyl 
                 — 
               
               
                 105 
                 N(CH 3 ) 
                 CH 2 -pyrrolidin-1-yl 
                 — 
               
               
                 108 
                 N(CH 3 ) 
                 OCH 3   
                 — 
               
               
                 109 
                 N(CH 3 ) 
                 OCH 3   
                 CH 3   
               
               
                 110 
                 N(CH 3 ) 
                 3,6-dihydro-2H-pyran-4-yl 
                 — 
               
               
                 111 
                 N(CH 3 ) 
                 tetrahydro-2H-pyran-4-yl 
                 — 
               
               
                 112 
                 N(CH 3 ) 
                 CHF 2   
                 — 
               
               
                 113 
                 N(CH 3 ) 
                 OC(CH 3 ) 2 (CH 2 ) 2 OH 
                 — 
               
               
                 114 
                 N(CH 3 ) 
                 O(CH 2 ) 2 C(CH 3 ) 2 OH 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia14) or a form thereof, wherein substituents X and B, when present, are indicated in the table below; and, “--” indicates that one or more X and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 55 
                 O 
                 piperidin-4-yl 
               
               
                 56 
                 O 
                 (2S,4R,6R)-2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 57 
                 O 
                 2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 58 
                 O 
                 pyrrolidin-3-yl 
               
               
                 59 
                 O 
                 2-CH 3 -piperidin-4-yl 
               
               
                 60 
                 OCH 2   
                 1H-pyrrolidin-3-yl 
               
               
                 61 
                 O 
                 3-F-piperidin-4-yl 
               
               
                 65 
                 — 
                 piperazin-1-yl 
               
               
                 67 
                 NH 
                 azetidin-3-yl 
               
               
                 68 
                 — 
                 3,5-(CH 3 ) 2 -piperazin-1-yl 
               
               
                 69 
                 — 
                 7-CH 3 -2,7-diazaspiro[4.4]non-2-yl 
               
               
                 70 
                 — 
                 [1,4]diazepan-1-yl 
               
               
                 71 
                 — 
                 4-CH 2 CH 2 OH-piperazin-1-yl 
               
               
                 72 
                 — 
                 2,7-diazaspiro[3.5]non-7-yl 
               
               
                 73 
                 — 
                 2,7-diazaspiro[3.5]non-7-yl 
               
               
                 74 
                 — 
                 3-CH 2 OH-piperazin-1-yl 
               
               
                 75 
                 — 
                 1,7-diazaspiro[4.4]non-7-yl 
               
               
                 76 
                 — 
                 4-NH 2 -4-CH 3 -piperidin-1-yl 
               
               
                 77 
                 — 
                 3-N(CH 3 ) 2 -piperidin-1-yl 
               
               
                 79 
                 — 
                 3,3-(CH 3 ) 2 -piperazin-1-yl 
               
               
                 80 
                 — 
                 7-CH 2 CH 2 OH-2,7-diazaspiro[4.4]-nonan-2-yl 
               
               
                 83 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 84 
                 — 
                 piperidin-4-yl 
               
               
                 102 
                 O 
                 (6S)-6-[(S)-CH(OH)CH 3 ]-2,2-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 133 
                 O 
                 2,2-(CH 3 ) 2 -piperidin-4-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia15) or a form thereof, wherein substituents X, R 1a  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 R 1a   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 3 
                 NH 
                 H 
                 — 
               
               
                 7 
                 N(CH 3 ) 
                 H 
                 — 
               
               
                 27 
                 N(CH 3 ) 
                 Cl 
                 CH 3   
               
               
                 29 
                 NH 
                 Cl 
                 CH 3   
               
               
                 36 
                 N(CH 3 ) 
                 OCH 3   
                 — 
               
               
                 38 
                 N(CH 3 ) 
                 F 
                 — 
               
               
                 39 
                 N(CH 3 ) 
                 CN 
                 — 
               
               
                 42 
                 N(CH 3 ) 
                 C(O)NHCH 2 CH═CH 2   
                 — 
               
               
                 43 
                 N(CH 3 ) 
                 1H-pyrazol-1-yl 
                 — 
               
               
                 44 
                 N(CH 3 ) 
                 5-CH 3 -oxazol-2-yl 
                 — 
               
               
                 45 
                 N(CH 3 ) 
                 4-CH 2 OH-1H-pyrazole-1-yl 
                 — 
               
               
                 46 
                 N(CH 3 ) 
                 1H-imidazole-1-yl 
                 — 
               
               
                 47 
                 N(CH 3 ) 
                 4-NH 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 48 
                 N(CH 3 ) 
                 1H-pyrazol-4-yl 
                 — 
               
               
                 49 
                 N(CH 3 ) 
                 3-NH 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 50 
                 N(CH 3 ) 
                 1-(CH 2 CH 2 -morpholin-4-yl)-1H- 
                 — 
               
               
                   
                   
                 pyrazol-4-yl 
                   
               
               
                 51 
                 N(CH 3 ) 
                 1-CH 3 -1H-pyrazol-4-yl 
                 — 
               
               
                 52 
                 N(CH 3 ) 
                 5-NH 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 54 
                 N(CH 2 CH 2 OH) 
                 1H-pyrazol-1-yl 
                 — 
               
               
                 62 
                 O 
                 1H-pyrazol-1-yl 
                 CH 3   
               
               
                 63 
                 O 
                 1H-pyrazol-1-yl 
                 — 
               
               
                 64 
                 O 
                 1H-pyrazol-4-yl 
                 — 
               
               
                 78 
                 NH 
                 1H-pyrazol-1-yl 
                 CH 3   
               
               
                 100 
                 CH 2   
                 1H-pyrazol-1-yl 
                 — 
               
               
                 130 
                 N(CH 3 ) 
                 Cl 
                 — 
               
               
                 131 
                 NH 
                 1H-pyrazol-1-yl 
                 — 
               
               
                 132 
                 NH 
                 CN 
                 — 
               
               
                 143 
                 N(CH 3 ) 
                 1H-indazol-7-yl 
                 — 
               
               
                 157 
                 CH 2   
                 1H-pyrazol-4-yl 
                 — 
               
               
                 168 
                 N(CH 3 ) 
                 5-OCH 3 -pyridin-3-yl 
                 — 
               
               
                 169 
                 N(CH 3 ) 
                 5-pyridin-2-ol 
                 — 
               
               
                 170 
                 N(CH 3 ) 
                 4-pyridin-2-ol 
                 — 
               
               
                 171 
                 N(CH 3 ) 
                 6-OCH 3 -pyridin-3-yl 
                 — 
               
               
                 172 
                 N(CH 3 ) 
                 5-(3-CF 3 -pyridin-2-ol) 
                 — 
               
               
                 173 
                 N(CH 3 ) 
                 5-(1-CH 3 -pyridin-2(1H)-one) 
                 — 
               
               
                 174 
                 N(CH 3 ) 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 — 
               
               
                 175 
                 N(CH 3 ) 
                 2-OCH 3 -pyridin-4-yl 
                 — 
               
               
                 176 
                 O 
                 4-pyridin-2-ol 
                 — 
               
               
                 177 
                 N(CH 3 ) 
                 6-N(CH 3 ) 2 -pyridin-3-yl 
                 — 
               
               
                 178 
                 O 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 — 
               
               
                 179 
                 N(CH 3 ) 
                 pyrimidin-5-yl 
                 — 
               
               
                 180 
                 N(CH 3 ) 
                 5-pyridin-3-ol 
                 — 
               
               
                 181 
                 N(CH 3 ) 
                 4-(1-cyclopropyl-pyridin-2(1H)- 
                 — 
               
               
                   
                   
                 one) 
                   
               
               
                 182 
                 N(CH 3 ) 
                 1,2,3,6-tetrahydropyridin-4-yl 
                 — 
               
               
                 183 
                 N(CH 3 ) 
                 cyclopent-1-en-1-yl 
                 — 
               
               
                 184 
                 N(CH 3 ) 
                 3,6-dihydro-2H-pyran-4-yl 
                 — 
               
               
                 185 
                 N(CH 3 ) 
                 imidazo[1,5-a]pyridin-7-yl 
                 — 
               
               
                 186 
                 N(CH 3 ) 
                 imidazo[1,2-a]pyridin-7-yl 
                 — 
               
               
                 187 
                 N(CH 3 ) 
                 2-CH 3 -pyridin-4-yl 
                 — 
               
               
                 188 
                 N(CH 3 ) 
                 1H-imidazol-2-yl 
                 — 
               
               
                 189 
                 N(CH 3 ) 
                 1H-imidazol-4-yl 
                 — 
               
               
                 190 
                 N(CH 3 ) 
                 imidazo[1,2-a]pyrazin-3-yl 
                 — 
               
               
                 191 
                 N(CH 3 ) 
                 5,6,7,8-tetrahydroimidazo[1,2- 
                 — 
               
               
                   
                   
                 a]pyrazin-3-yl 
                   
               
               
                 192 
                 N(CH 3 ) 
                 4-CH 3 -1H-imidazol-2-yl 
                 — 
               
               
                 193 
                 N(CH 3 ) 
                 1-CH 3 -1H-imidazol-4-yl 
                 — 
               
               
                 194 
                 N(CH 3 ) 
                 1-CH 3 -1H-imidazol-5-yl 
                 — 
               
               
                 195 
                 N(CH 3 ) 
                 4-NO 2 -1H-imidazol-2-yl 
                 — 
               
               
                 196 
                 N(CH 3 ) 
                 2-CH 3 -1H-imidazol-4-yl 
                 — 
               
               
                 197 
                 N(CH 3 ) 
                 1,2-(CH 3 ) 2 -1H-imidazol-4-yl 
                 — 
               
               
                 198 
                 N(CH 3 ) 
                 4-C(O)NH 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 206 
                 N(CH 3 ) 
                 H 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the present description includes a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia15) or a form thereof, wherein substituents X, R 1a  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 R 1a   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 413 
                 NH 
                 1H-pyrazol-4-yl 
                 — 
               
               
                 414 
                 O 
                 1-CH 3 -1H-pyrazol-4-yl 
                 — 
               
               
                 416 
                 N(CH 3 ) 
                 5-CH 3 -1H-pyrazol-4-yl 
                 — 
               
               
                 417 
                 O 
                 1H-imidazol-1-yl 
                 — 
               
               
                 418 
                 O 
                 5-CH 3 -1H-pyrazol-4-yl 
                 — 
               
               
                 419 
                 N(CH 3 ) 
                 4-NO 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 421 
                 O 
                 4-NH 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 423 
                 O 
                 4-NO 2 -1H-pyrazol-1-yl 
                 — 
               
               
                 460 
                 N(CH 3 ) 
                 1H-pyrazol-4-yl 
                 — 
               
               
                 461 
                 O 
                 1H-pyrazol-4-yl 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia15) or a form thereof, wherein substituents X, R 1a  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 R 1a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 413 
                 NH 
                 1H-pyrazol-4-yl 
               
               
                 414 
                 O 
                 1-CH 3 -1H-pyrazol-4-yl 
               
               
                 416 
                 N(CH 3 ) 
                 5-CH 3 -1H-pyrazol-4-yl 
               
               
                 417 
                 O 
                 1H-imidazol-1-yl 
               
               
                 418 
                 O 
                 5-CH 3 -1H-pyrazol-4-yl 
               
               
                 419 
                 N(CH 3 ) 
                 4-NO 2 -1H-pyrazol-1-yl 
               
               
                 421 
                 O 
                 4-NH 2 -1H-pyrazol-1-yl 
               
               
                 423 
                 O 
                 4-NO 2 -1H-pyrazol-1-yl 
               
               
                 460 
                 N(CH 3 ) 
                 1H-pyrazol-4-yl 
               
               
                 461 
                 O 
                 1H-pyrazol-4-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia16) or a form thereof, wherein substituents R 1a  and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more R 1a  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 81 
                 1H-pyrazol-1-yl 
                 — 
               
               
                 199 
                 1H-pyrazol-4-yl 
                 (CH 2 ) 2 OH 
               
               
                 200 
                 1H-pyrazol-4-yl 
                 — 
               
               
                 201 
                 1H-pyrazol-4-yl 
                 CH 3   
               
               
                 202 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 CH 3   
               
               
                 203 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 CH 3   
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia17) or a form thereof, wherein substituent R 1a , when present, is indicated in the table below; and, “--” indicates that one or more R 1a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 204 
                 1H-pyrazol-4-yl 
               
               
                 205 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the present description includes a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia18) or a form thereof, wherein substituents X and B, when present, are indicated in the table below; and, “--” indicates that one or more X and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 411 
                 N(CH 3 ) 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 412 
                 NH 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 415 
                 O 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 422 
                 — 
                 1-CH 3 -(1,2,3,6-tetrahydropyridin-4-yl) 
               
               
                 424 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 425 
                 — 
                 1-CH 3 CH 2 -(1,2,3,6-tetrahydropyridin-4-yl) 
               
               
                 426 
                 N(CH 3 ) 
                 piperidin-4-yl 
               
               
                 427 
                 NH 
                 piperidin-4-yl 
               
               
                 429 
                 — 
                 8-azabicyclo[3.2.1]oct-2-en-3-yl 
               
               
                 432 
                 O 
                 piperidin-4-yl 
               
               
                 433 
                 NH 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 436 
                 O 
                 2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 439 
                 — 
                 2,7-diazaspiro[3.5]non-2-yl 
               
               
                 441 
                 O 
                 2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 459 
                 — 
                 2,6-diazaspiro[3.4]oct-2-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ia) or a form thereof selected from a compound of Formula (Ia18) or a form thereof, wherein substituents X, R 1a  and B, when present, are indicated in the table below; and, “--” indicates that one or more X, R 1a  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
             
               
                   
               
               
                 Cpd 
                 X 
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 411 
                 N(CH 3 ) 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 412 
                 NH 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 415 
                 O 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 422 
                 — 
                 1-CH 3 -(1,2,3,6-tetrahydropyridin-4-yl) 
               
               
                 424 
                 — 
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 425 
                 — 
                 1-CH 3 CH 2 -(1,2,3,6-tetrahydropyridin-4-yl) 
               
               
                 426 
                 N(CH 3 ) 
                 piperidin-4-yl 
               
               
                 427 
                 NH 
                 piperidin-4-yl 
               
               
                 429 
                 — 
                 8-azabicyclo[3.2.1]oct-2-en-3-yl 
               
               
                 432 
                 O 
                 piperidin-4-yl 
               
               
                 433 
                 NH 
                 (1R,5S)-8-azabicyclo[3.2.1]oct-3-yl 
               
               
                 436 
                 O 
                 2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 439 
                 — 
                 2,7-diazaspiro[3.5]non-2-yl 
               
               
                 441 
                 O 
                 2,6-(CH 3 ) 2 -piperidin-4-yl 
               
               
                 459 
                 — 
                 2,6-diazaspiro[3.4]oct-2-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib1) or a form thereof, wherein substituent A is indicated in the table below: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 A 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 302 
                 6-(naphthalen-2-ol) 
               
               
                 320 
                 6-(naphthalen-2,7-diol) 
               
               
                 331 
                 7-OCH 3 -quinolin-6-yl 
               
               
                 332 
                 7-OH-quinolin-6-yl 
               
               
                 337 
                 2-CN-7-OCH 3 -quinolin-6-yl 
               
               
                 355 
                 3-F-5-(1H-pyrazol-4-yl)-pyridin-2-yl 
               
               
                 364 
                 2-(6-OCH 3 -3,4-dihydroisoquinolin-1(2H)-one) 
               
               
                 392 
                 6-OH-1-oxo-2,3-dihydro-1H-inden-5-yl 
               
               
                 401 
                 3-(4-OCH 3 -1-CH 3 -quinolin-2(1H)-one) 
               
               
                 402 
                 3-(4-OH-1-CH 3 -quinolin-2(1H)-one) 
               
               
                 403 
                 3-(quinolin-2(1H)-one) 
               
               
                 404 
                 3-(1-OCH 3 -quinolin-2(1H)-one) 
               
               
                 408 
                 5-CN-benzo[b]thiophen-2-yl 
               
               
                 409 
                 3-Cl-benzo[b]thiophen-2-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the present description includes a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib1) or a form thereof, wherein substituent A is indicated in the table below: c 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 A 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 462 
                 3-(1H-pyrazol-4-yl)phenoxy 
               
               
                 463 
                 4-(1H-pyrazol-4-yl)phenoxy 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib1) or a form thereof, wherein substituent A is indicated in the table below: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 A 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 462 
                 3-(1H-pyrazol-4-yl)phenoxy 
               
               
                 463 
                 4-(1H-pyrazol-4-yl)phenoxy 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib2) or a form thereof, wherein substituent A is indicated in the table below: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 A 
               
               
                   
               
             
            
               
                 321 
                 6-naphthalen-2,7-diol 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib3) or a form thereof, wherein substituents R 1a , R 1b  and B, when present, are indicated in the table below; and, “--” indicates that one or more R 1a , R 1b  and B substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 B 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 329 
                 1H-pyrazol-1-yl 
                 OCH 3   
                 1,2,3,6-tetrahydropyridin-4-yl 
               
               
                 330 
                 1H-pyrazol-1-yl 
                 OH 
                 piperazin-1-yl 
               
               
                 381 
                 1H-pyrazol-1-yl 
                 Cl 
                 5-((3aR,6aR)-1-CH 3 -hexahydropyrrolo[3,4- 
               
               
                   
                   
                   
                 b]pyrrol-5(lH)-yl) 
               
               
                 382 
                 1H-pyrazol-1-yl 
                 Cl 
                 2-NHCH(CH 3 ) 2 -morpholin-4-yl 
               
               
                 383 
                 1H-pyrazol-1-yl 
                 Cl 
                 2-OCH 3 -2,7-diazaspiro[4.5]decan-7-yl 
               
               
                 385 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OCH 3   
                 5-((3aR,6aS)-5-CH 3 -hexahydropyrrolo[3,4- 
               
               
                   
                   
                   
                 c]pyrrol-2(1H)-yl) 
               
               
                 394 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OH 
                 5-((3aR,6aS)-5-CH 3 -hexahydropyrrolo[3,4- 
               
               
                   
                   
                   
                 c]pyrrol-2(1H)-yl) 
               
               
                 406 
                 1H-pyrazol-1-yl 
                 Cl 
                 2,7-diazaspiro[4.5]decan-2-yl 
               
               
                 407 
                 1H-pyrazol-1-yl 
                 Cl 
                 (3R)-(3-(R)-CH 2 OH)-piperazin-1-yl 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib4) or a form thereof, wherein substituents R 1a , R 1b , R 1c , R 1d  (each representative of the scope of R 1 ) and X, when present, are indicated in the table below; and, “--” indicates that one or more R 1a , R 1b , R 1c , R 1d  and X substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 R 1c   
                 R 1d   
                 X 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 301 
                 1H-pyrazol-1-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 305 
                 1H-pyrazol-1-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 306 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 307 
                 1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 308 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 309 
                 5-pyridin-2-ol 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 310 
                 5-(1-CH 3 -pyridin-2(1H)-one) 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 311 
                 1-CH 3 -1H-pyrazol-4-yl 
                 CH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 312 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 OCF 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 313 
                 3,5-(CH 3 ) 2 -1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 314 
                 1-CH 3 -1H-pyrazol-4-yl 
                 CF 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 315 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 316 
                 1H-pyrazol-1-yl 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 317 
                 5-(1-CH 3 -pyridin-2(1H)-one) 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 318 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 319 
                 5-pyridin-2-ol 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 324 
                 H 
                 OH 
                 1H-pyrazol-1-yl 
                 H 
                 N(CH 3 ) 
               
               
                 325 
                 1-CH 3 -1H-pyrazol-4-yl 
                 H 
                 H 
                 Cl 
                 N(CH 3 ) 
               
               
                 326 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OH 
                 H 
                 Cl 
                 N(CH 3 ) 
               
               
                 327 
                 1-CH 3 -1H-pyrazol-4-yl 
                 H 
                 H 
                 Cl 
                 N(CH 3 ) 
               
               
                 328 
                 5-CH 3 -oxazol-2-yl 
                 OH 
                 H 
                 OCH 3   
                 N(CH 3 ) 
               
               
                 333 
                 CN 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 334 
                 CN 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 335 
                 CO 2 CH 3   
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 336 
                 3-NHCH 3 -1H-pyrazol-1-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 338 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 339 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 340 
                 1H-pyrazol-4-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 341 
                 4,5,6,7- 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                   
                 tetrahydropyrazolo[1,5-a] 
                   
                   
                   
                   
               
               
                   
                 pyridin-3-yl 
                   
                   
                   
                   
               
               
                 343 
                 1-CH 3 -1H-pyrazol-4-yl 
                 Cl 
                 H 
                 H 
                 O 
               
               
                 344 
                 6-OCH 3 -pyridin-3-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 345 
                 6-NH 2 -pyridin-3-yl 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 346 
                 3-CH 3 -1H-pyrazol-5-yl 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 347 
                 1H-pyrazol-5-yl 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 348 
                 1H-pyrazol-4-yl 
                 H 
                 F 
                 F 
                 N(CH 3 ) 
               
               
                 349 
                 1H-pyrazol-5-yl 
                 H 
                 F 
                 F 
                 N(CH 3 ) 
               
               
                 350 
                 1H-pyrazol-4-yl 
                 F 
                 F 
                 H 
                 N(CH 3 ) 
               
               
                 351 
                 1H-pyrazol-5-yl 
                 F 
                 F 
                 H 
                 N(CH 3 ) 
               
               
                 352 
                 1H-pyrazol-4-yl 
                 F 
                 H 
                 F 
                 N(CH 3 ) 
               
               
                 354 
                 1H-pyrazol-4-yl 
                 Cl 
                 F 
                 H 
                 N(CH 3 ) 
               
               
                 356 
                 2-NH 2 -pyrimidin-4-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 357 
                 H 
                 Cl 
                 2-NH 2 -pyrimidin- 
                 H 
                 N(CH 3 ) 
               
               
                   
                   
                   
                 4-yl 
                   
                   
               
               
                 358 
                 2,4-(CH 3 ) 2 -thiazol-5-yl 
                 F 
                 F 
                 H 
                 N(CH 3 ) 
               
               
                 359 
                 2,4-(CH 3 ) 2 -thiazol-5-yl 
                 H 
                 F 
                 F 
                 N(CH 3 ) 
               
               
                 360 
                 4-(1-CH 3 -pyridin-2(1H)-one) 
                 OH 
                 H 
                 OCF 3   
                 N(CH 3 ) 
               
               
                 361 
                 1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 F 
                 N(CH 3 ) 
               
               
                 363 
                 1H-pyrazol-4-yl 
                 OCH 3   
                 F 
                 F 
                 N(CH 3 ) 
               
               
                 365 
                 1H-pyrazol-1-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 366 
                 1H-1,2,3-triazol-1-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 367 
                 2H-1,2,3-triazol-2-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 368 
                 1H-1,2,4-triazol-1-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 369 
                 3-NH 2 -1H-pyrazol-1-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 371 
                 1H-imidazol-1-yl 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 372 
                 1H-imidazol-1-yl 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 373 
                 1H-pyrazol-5-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 374 
                 2,4-(CH 3 ) 2 -thiazol-5-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 375 
                 pyridin-3-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 376 
                 1H-pyrazol-4-yl 
                 F 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 377 
                 2-OCH 3 -pyridin-4-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 378 
                 6-OCH 3 -pyridin-3-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 387 
                 1H-pyrazol-1-yl 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 388 
                 5-(pyridin-2(1H)-one) 
                 Cl 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 389 
                 3-NHCH 3 -1H-pyrazol-1-yl 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 390 
                 1H-pyrazol-4-yl 
                 OH 
                 H 
                 F 
                 N(CH 3 ) 
               
               
                 391 
                 1H-pyrazol-4-yl 
                 OH 
                 F 
                 F 
                 N(CH 3 ) 
               
               
                 393 
                 1H-pyrazol-4-yl 
                 OH 
                 H 
                 H 
                 N(CH 3 ) 
               
               
                 397 
                 1H-pyrazol-4-yl 
                 OH 
                 H 
                 Cl 
                 N(CH 3 ) 
               
               
                 398 
                 1H-pyrazol-1-yl 
                 OCH 3   
                 H 
                 H 
                 CH 2   
               
               
                 410 
                 1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 H 
                 N(CH 3 ) 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib5) or a form thereof, wherein substituents R 1a , R 1b , R 1c , R 1d  (each representative of the scope of R 1 ) and R 4a , when present, are indicated in the table below; and, “--” indicates that one or more R 1a , R 1b , R 1c , R 1d  and R 4a  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 R 1c   
                 R 1d   
                 R 4a   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 353 
                 1H-pyrazol-4-yl 
                 F 
                 F 
                 H 
                 — 
               
               
                 362 
                 1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 F 
                 CH 3   
               
               
                 370 
                 1H-imidazol-1-yl 
                 Cl 
                 H 
                 H 
                 CH 3   
               
               
                 379 
                 1-CH 3 -1H-pyrazol-4-yl 
                 Cl 
                 H 
                 H 
                 CH 3   
               
               
                 380 
                 1H-pyrazol-4-yl 
                 Cl 
                 H 
                 H 
                 CH 3   
               
               
                 384 
                 1H-pyrazol-4-yl 
                 F 
                 H 
                 H 
                 CH 3   
               
               
                 396 
                 1H-pyrazol-4-yl 
                 F 
                 H 
                 OH 
                 — 
               
               
                 405 
                 1H-pyrazol-4-yl 
                 Cl 
                 H 
                 H 
                 — 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib6) or a form thereof, wherein substituents R 1a , R 1b , R 1c  and R 1d  (each representative of the scope of R 1 ), when present, are indicated in the table below; and, “--” indicates that one or more R 1a , R 1b , R 1c  and R 1d  substituents are not present: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
               
               
               
             
               
                   
               
               
                 Cpd 
                 R 1a   
                 R 1b   
                 R 1c   
                 R 1d   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 386 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OCH 3   
                 H 
                 H 
               
               
                 395 
                 1-CH 3 -1H-pyrazol-4-yl 
                 OH 
                 H 
                 H 
               
               
                 399 
                 1H-pyrazol-4-yl 
                 H 
                 F 
                 F 
               
               
                 400 
                 1H-pyrazol-4-yl 
                 OH 
                 H 
                 F 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib7) or a form thereof, wherein substituent R 1b , when present, is indicated in the table below: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 R 1b   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 304 
                 OCH 3   
               
               
                 322 
                 OH 
               
               
                   
               
            
           
         
       
     
     Another embodiment of the method of the present description includes the use of a compound of Formula (Ib) or a form thereof selected from a compound of Formula (Ib8) or a form thereof, wherein substituent R 1b , when present, is indicated in the table below: 
     
       
         
         
             
             
         
       
     
     
       
         
           
               
            
               
                   
               
               
                 (Ib8) 
               
            
           
           
               
               
               
            
               
                   
                 Cpd 
                 R 1b   
               
               
                   
               
               
                   
                 303 
                 OCH 3   
               
               
                   
                 323 
                 OH 
               
               
                   
               
            
           
         
       
     
     An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject, selected from the group consisting of: 
     
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
       
         
         
             
             
         
       
     
                                                                                                                                                                                                                                                                                                                                                                                                                                     
wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     In another aspect, the compound of Formula (I) or a form thereof includes a compound selected from the group consisting of: 
                                                                                                                                                                                                             
wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     Another embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof (wherein compound number (# 1 ) indicates that the salt form was isolated) to the subject, selected from the group consisting of: 
                                 Cpd   Name                   1   6-(naphthalen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        2   6-(benzo[b]thiophen-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-           amine        3   2-(6-(2,2,6,6-tetramethylpiperidin-4-yl-amino)-pyridazin-3-yl)phenol        4   2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)benzo[b]-           thiophene-5-carbonitrile        5   6-(quinolin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        6   3-(benzo[b]-thiophen-2-yl)-6-(2,2,6,6-tetramethylpiperidin-4-yl-oxy)pyridazine        7   2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyridazin-3-yl)phenol        8   6-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyridazin-3-yl)naphthalen-2-ol        9   6-(benzo[b]-thiophen-2-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        10   7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)isoquinoline        11   6-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)isoquinoline        12   N-methyl-6-(quinolin-7-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        13   N-methyl-6-(quinolin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        14   6-(isoquinolin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        15   6-(isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        16   6-(imidazo[1,2-a]pyridin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine        17   N-methyl-6-(6-phenylpyridin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-           amine        18   6-(6-(1H-pyrrol-1-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine        19   6-(6-(1H-pyrazol-1-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine        20   methyl-(6-quinoxalin-2-yl-pyridazin-3-yl)-(2,2,6,6-tetramethylpiperidin-4-yl)-amine        21   methyl-(6-quinolin-3-yl-pyridazin-3-yl)-(2,2,6,6-tetramethylpiperidin-4-yl)-amine        22   N-methyl-6-(phthalazin-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        23   6-(benzo[c][1,2,5]oxa-diazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-           amine        24   6-(benzo[d]thiazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine        25   6-(2-methylbenzo-[d]oxazol-6-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-           amine        26   3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)naphthalen-2-ol        27   5-chloro-2-(6-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol        28   3-(6-(2,2,6,6-tetramethylpiperidin-4-yl-amino)pyridazin-3-yl)naphthalen-2-ol        29   5-chloro-2-(6-(1,2,2,6,6-pentamethylpiperidin-4-ylamino)pyridazin-3-yl)phenol        30   4-hydroxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)benzonitrile        31   3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)naphthalen-2-ol           32 1     2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (trifluoromethyl)phenol        33   2-fluoro-6-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-pyridazin-3-yl)phenol        34   3,5-dimethoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol        35   4,5-dimethoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol        36   5-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol        37   4,5-difluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol        38   5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol        39   3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)benzonitrile        40   1-allyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalen-2-ol        41   6-(benzo[b]thiophen-2-yl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)pyridazin-3-amine        42   N-allyl-3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)benzamide        43   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-1-           yl)phenol        44   5-(5-methyl-oxazol-2-yl)-2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-           pyridazin-3-yl)phenol        45   5-(4-(hydroxymethyl)-1H-pyrazole-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol        46   5-(1H-imidazol-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenol        47   5-(4-amino-1H-pyrazole-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol        48   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-           yl)phenol        49   5-(3-amino-1H-pyrazol-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol        50   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-(2-           morpholino-ethyl)-1H-pyrazol-4-yl)phenol        51   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-methyl-1H-           pyrazol-4-yl)phenol        52   5-(5-amino-1H-pyrazol-1-yl)-2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol           53 1     2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-1-           yl)phenol        54   2-((6-((2-hydroxy-ethyl)-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-pyridazin-3-yl)-5-           pyrazol-1-yl)phenol        55   2-(6-(piperidin-4-yloxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        56   2-(6-(((2S,4R,6R)-2,6-dimethylpiperidin-4-yl)oxy)pyridazin-3-yl)-5-(1H-pyrazol-1-           yl)phenol        57   2-(6-((-2,6-dimethylpiperidin-4-yl)oxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        58   5-(1H-pyrazol-1-yl)-2-(6-(pyrrolidin-3-yl-oxy)pyridazin-3-yl)phenol        59   2-(6-(((2S,4S)-2-methylpiperidin-4-yl)oxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        60   (5-(1H-pyrazol-1-yl)-2-(6-(pyrrolidin-3-ylmethoxy)pyridazin-3-yl)phenol        61   2-(6-((3-fluoropiperidin-4-yl)oxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        62   2-(6-(1,2,2,6,6-pentamethyl-piperidin-4-yl-oxy)-pyridazin-3-yl)-5-(1H-pyrazol-1-           yl)phenol        63   5-1H-pyrazol-1-yl-2-(6-(2,2,6,6-tetramethylpiperidin-4-yl-oxy)-pyridazin-3-yl)phenol        64   5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenol           65 1     2-(6-piperazin-1-yl-pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        66   3-(6-(azetidin-3-ylamino)-pyridazin-3-yl)naphthalen-2-ol        67   2-(6-(azetidin-3-ylamino)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        68   2-(6-(3,5-dimethylpiperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        69   2-(6-(7-methyl-2,7-diazaspiro[4.4]nonan-2-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-           yl)phenol        70   2-(6-(1,4-diazepan-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        71   2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        72   2-(6-(3,6-diazabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        73   2-(6-(2,7-diazaspiro[3.5]nonan-7-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        74   2-(6-(3-(hydroxymethyl)piperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        75   2-(6-(1,7-diazaspiro[4.4]nonan-7-yl)pyridazin-3-y1)-5-(1H-pyrazol-1-yl)phenol        76   2-(6-(4-amino-4-methylpiperidin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        77   2-(6-(3-(dimethylamino)piperidin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        78   2-(6-(1,2,2,6,6-pentamethylpiperidin-4-ylamino)-pyridazin-3-yl)-5-1H-pyrazol-1-yl-           phenol        79   2-(6-(3,3-dimethylpiperazin-1-yl)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol        80   2-(6-(7-(2-hydroxyethyl)-2,7-diazaspiro[4.4]-nonan-2-yl)pyridazin-3-yl)-5-(1H-pyrazol-           1-yl)phenol        81   2-(6-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-yl)-5-(1H-           pyrazol-1-yl)phenol           82 1     3-(6-(piperazin-1-yl)pyridazin-3-yl)naphthalene-2,7-diol        83   5-(1H-pyrazol-1-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)phenol        84   2-(6-piperidin-4-yl-pyridazin-3-yl)-5-1H-pyrazol-1-yl-phenol        85   3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalen-2-ol           86 1     3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol        87   3-(6-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2,7-           diol           88 1     3-(6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol           89 1     3-(6-(piperidin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol        90   3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)naphthalene-2,7-diol        91   3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)naphthalene-2,7-           diol        92   3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)naphthalene-2,7-diol        93   tert-butyl(3-((7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)naphthalen-2-yl)oxy)propyl)carbamate        94   7-(3-amino-propoxy)-3-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-           pyridazin-3-yl)naphthalen-2-ol        95   N-(3-((7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalen-2-yl)oxy)propyl)acetamide        96   7-(3-hydroxypropoxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)naphthalen-2-ol        97   7-(3-methoxypropoxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)naphthalen-2-ol        98   7-(2-morpholinoethoxy)-3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)naphthalen-2-ol        99   3-(6-(piperidin-4-ylmethyl)pyridazin-3-yl)naphthalen-2-ol       100   5-(1H-pyrazol-1-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)methyl)pyridazin-3-           yl)phenol       101   3-methoxy-2-(6-(methyl(2,2,6-trimethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5-           methyloxazol-2-yl)phenol       102   2-(6-((6S)-6-((S)-1-hydroxyethyl)-2,2-dimethylpiperidin-4-yloxy)pyridazin-3-yl)-5-           (1H-pyrazol-1-yl)phenol       103   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2-           naphthonitrile       104   3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-7-           (piperidinylmethyl)naphthalen-2-ol       105   3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-7-           (pyrrolidinylmethyl)naphthalen-2-ol       106   1-bromo-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalene-2,7-diol       107   1-chloro-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalene-2,7-diol       108   7-methoxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalene-2-ol       109   7-methoxy-3-(6-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalen-2-ol       110   7-(3,6-dihydro-2H-pyran-4-yl)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)naphthalen-2-ol       111   3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-7-(tetrahydro-2H-           pyran-4-yl)naphthalene-2-ol       112   7-(difluoromethyl)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)naphthalen-2-ol       113   7-((4-hydroxy-2-methylbutan-2-yl)oxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)naphthalen-2-ol       114   7-(3-hydroxy-3-methylbutoxy)-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)naphthalen-2-ol       115   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-           yl)benzene-1,3-diol       116   3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-           (1H-pyrazol-4-yl)phenol       117   5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-3-           (trifluoromethoxy)phenol       118   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-methyl-1H-           pyrazol-4-yl)-3-(trifluoromethoxy)phenol       119   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-pyrazol-4-           yl)-3-(trifluoromethoxy)phenol       120   4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-           (trifluoromethoxy)phenyl)-1-methylpyridin-2(1H)-one       121   3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-           methyl-1H-pyrazol-4-yl)phenol       122   3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-           (5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)phenol       123   3-methoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-           (pyridine-3-yl)phenol       124   5-(1-cyclopentyl-1H-pyrazol-4-yl)-3-methoxy-2-(6-(methyl(2,2,6,6-           tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol       125   3′,5-dimethoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-           (1,1′-biphenyl)-3-ol       126   3-(benzyloxy)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-           (5-methyloxazol-2-yl)phenol       127   3-ethoxy-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5-           methyloxazol-2-yl)phenol       128   3-(cyclopropylmethoxy)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-           pyridazin-3-yl)-5-(5-methyloxazol-2-yl)phenol       129   2-methyl-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-1H-           benzo[d]imidazol-6-ol       130   5-chloro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenol       131   5-(1H-pyrazol-1-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol       132   3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)benzonitrile       133   2-(6-((2,2-dimethylpiperidin-4-yl)oxy)pyridazin-3-yl)-5-(1H-pyrazol-1-yl)phenol       134   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-4-           yl)phenol       135   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(4,5,6,7-           tetrahydropyrazolo[1,5-a]pyridin-3-yl)phenol       136   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(4,5,6,7-           tetrahydropyrazolo[1,5-a]pyrazin-3-yl)phenol       137   4-(1H-indol-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol       138   4-(cyclopent-1-en-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       139   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-3-           yl)phenol       140   4-(4-hydroxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)pyridin-2-ol       141   4-(4-hydroxy-3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenyl)-1-           methylpyridin-2(1H)-one       142   4-(4-hydroxy-3-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)phenyl)pyridin-2-ol       143   5-(1H-indazol-7-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol       144   4-chloro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-           pyrazol-4-yl)phenol       145   4-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-           pyrazol-4-yl)phenol       146   5-fluoro-4-(1H-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       147   5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-           pyrazol-4-yl)phenol       148   5-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-           pyrazol-5-yl)phenol       149   6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2,3-           dihydro-1H-inden-1-one       150   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-1,4-           dihydroindeno[1,2-c]-1H-pyrazol-7-ol           151 1     6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2,3-           dihydro-1H-inden-1-oneoxime       152   5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2,3-dihydro-1H-           indene-l,6-diol           153 1     2-amino-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-8H-           indeno[1,2-d]thiazol-5-ol           154 1     9-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5,6-           dihydroimidazo[5,1-a]isoquinolin-8-ol       155   4-hydroxy-3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-N-((1-           methyl-1H-pyrazol-4-yl)methyl)benzamide       156   4-(4-(hydroxymethyl)-1H-pyrazol-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       157   5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)methyl)pyridazin-3-           yl)phenol       158   6-(3-(benzyloxy)isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       159   6-(1-(benzyloxy)isoquinolin-7-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine           160 1     3-fluoro-5-(2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol           161 1     4-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenyl)pyridin-2(1H)-one           162 1     4-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenyl)-1-methyipyridin-2(1H)-one           163 1     5-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenyl)-1-methyipyridin-2(1H)-one           164 1     3-fluoro-5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)phenol           165 1     5-chloro-3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol           166 1     3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-           pyrazol-4-yl)phenol           167 1     3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-           methyl-1H-pyrazol-4-yl)phenol       168   5-(5-methoxypyridin-3-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       169   5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)pyridin-2-ol       170   4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)pyridin-2-ol       171   5-(6-methoxypyridin-3-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       172   5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-3-(trifluoromethyl)pyridin-2-ol       173   5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-1-methyipyridin-2(1H)-one       174   4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-1-methyipyridin-2(1H)-one       175   5-(2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       176   4-(3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)phenyl)pyridin-2-ol       177   5-(6-(dimethylamino)pyridin-3-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       178   4-(3-hydroxy-4-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)phenyl)-1-           methylpyridin-2(1H)-one       179   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(pyrimidin-5-           yl)phenol       180   5-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)pyridin-3-ol       181   1-cyclopropyl-4-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenyl)pyridin-2(1H)-one       182   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1,2,3,6-           tetrahydropyridin-4-yl)phenol       183   5-(cyclopent-1-en-1-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       184   5-(3,6-dihydro-2H-pyran-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       185   5-(imidazo[1,5-a]pyridin-7-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       186   5-(imidazo[1,2-a]pyridin-7-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       187   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(2-           methylpyridin-4-yl)phenol       188   5-(1H-imidazol-2-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenol       189   5-(1H-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)phenol       190   5-(imidazo[1,2-a]pyrazin-3-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       191   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(5,6,7,8-           tetrahydroimidazo[1,2-a]pyrazin-3-yl)phenol       192   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-methyl-1H-           imidazol-2-yl)phenol       193   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-methyl-1H-           imidazol-4-yl)phenol       194   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-methyl-1H-           imidazol-5-yl)phenol       195   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-nitro-1H-           imidazol-2-yl)phenol       196   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(2-methyl-1H-           imidazol-4-yl)phenol       197   5-(1,2-dimethyl-1H-imidazol-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol       198   1-(3-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-1H-pyrazole-4-carboxamide       199   2-(6-((3aR,6aS)-5-(2-hydroxyethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-           3-yl)-5-(1H-pyrazol-4-yl)phenol       200   2-(6-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-yl)-5-(1H-           pyrazol-4-yl)phenol       201   2-(6-((3aR,6aS)-5-methy1Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-yl)-5-           (1H-pyrazol-4-yl)phenol       202   4-(3-hydroxy-4-(6-(5-methy1Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-           yl)phenyl)-1-methyipyridin-2(1H)-one       203   4-(3-hydroxy-4-(6-((3aR,6aR)-1-methy1Hexahydropyrrolo[3,4-b]pyrrol-5(1H)-           yl)pyridazin-3-yl)phenyl)-1-methylpyridin-2(1H)-one       204   2-(6-(2,7-diazaspiro[4.5]decan-2-yl)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol       205   4-(4-(6-(2,7-diazaspiro[4.5]decan-2-yl)pyridazin-3-yl)-3-hydroxyphenyl)-1-           methylpyridin-2(1H)-one       206   2-(6-(methyl-(2,2,6,6-tetramethylpiperidin-4-yl)-amino)-pyridazin-3-yl)phenol       207   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-7-ol       208   6-(6-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-7-ol       209   6-(6-((3aR,6aS)-5-methy1Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-           yl)quinolin-7-ol       210   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           7-ol       211   7-(6-(methyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino)pyridazin-3-yl)isoquinolin-6-ol       212   7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)isoquinolin-6-ol       213   7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)isoquinoline-6-ol       214   7-(6-((3aR,6aS)-5-methy1Hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyridazin-3-           yl)isoquinolin-6-ol       215   1-cyclopropyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       216   7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)isoquinoline-1,6-           diol       217   6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinoline-1-carbonitrile       218   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)isoquinolin-7-ol       219   8-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-7-ol       220   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-6-ol       221   2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol       222   3-chloro-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           7-ol       223   3-bromo-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           7-ol       224   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoline-3-carbonitrile       225   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-3-(1-methyl-1H-           imidazol-4-yl)quinolin-7-ol           226 1     3-(1H-imidazol-1-yl)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-           3-yl)quinolin-7-ol       227   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinoline-3,7-diol       228   3-ethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           7-ol       229   3-isopropyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       230   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-2(1H)-one           231 1     7-hydroxy-1-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-2(1H)-one       232   4-methoxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       233   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (pyrrolidin-1-yl)quinolin-7-ol       234   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           morpholinoquinolin-7-ol       235   4-(dimethylamino)-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)quinolin-7-ol       236   4-ethoxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       237   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1-           methyl-1H-pyrazol-4-yl)quinolin-7-ol           238 1     4-methoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-6-ol           239 1     7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinoxalin-6-ol       240   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-3-(tetrahydro-2H-           pyran-4-yl)quinolin-7-ol       241   3-chloro-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol       242   3-bromo-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol       243   3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol       244   5-bromo-3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-6-ol       245   6-hydroxy-1-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-4(1H)-one       246   2,3-dimethyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-6-ol       247   2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoxalin-6-ol       248   3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoxalin-6-ol       249   4-methoxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       250   4-(azetidin-1-yl)-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)quinolin-7-ol       251   7-hydroxy-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolone-4-carbonitrile       252   4-cyclopropyl-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)-quinolin-7-ol       253   4-(3,6-dihydro-2H-pyran-4-yl)-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)quinolin-7-ol           254 1     2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (tetrahydro-2H-pyran-4-yl)quinolin-7-ol       255   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (oxetan-3-yl)quinolin-7-ol           256 1     4-(dimethylamino)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)-quinolin-7-ol       257   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinazolin-4(1H)-one       258   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinazolin-7-ol       259   7-hydroxy-1-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)-3,4-dihydroquinolin-2(1H)-one       260   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinazolin-7-ol       261   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinoline-1-carbonitrile       262   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoline-2-carbonitrile       263   6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-2-carbonitrile       264   6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinoline-1-carboxamide       265   7-hydroxy-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-2-carboxamide       266   6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoline-2-carboxamide       267   methyl 6-hydroxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoline-2-carboxylate       268   6-hydroxy-7-(6-(piperazin-1-yl)pyridazin-3-yl)quinoline-2-carbonitrile       269   7-hydroxy-6-(6-(piperazin-1-yl)pyridazin-3-yl)quinoline-2-carbonitrile       270   7-(6-(piperazin-1-yl)pyridazin-3-yl)isoquinolin-6-ol       271   7-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)quinolin-6-ol       272   1-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-7-ol       273   1-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       274   1,3-dimethyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       275   7-hydroxy-3-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinoline-1-carbonitrile       276   1-amino-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       277   7-hydroxy-1,3-dimethyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)quinazoline-2,4(1H,3H)-dione       278   6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)benzo[d]oxazol-2(3H)-one       279   2-methyl-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2H-           indazol-6-ol       280   1-methyl-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-1H-           indazol-6-ol           281 1     6-hydroxy-2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-1(2H)-one       282   2-ethyl-6-hydroxy-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)isoquinolin-1(2H)-one       283   1-ethoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       284   7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-yl)isoquinoline-1,6-diol       285   7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-pyridazin-3-yl)-3-           phenylisoquinolin-6-ol       286   3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       287   3-cyclopropyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       288   3-isopropyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-6-ol       289   3-propyl-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)-pyridazin-3-yl)isoquinolin-6-ol       290   3-isopropyl-7-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)-pyridazin-3-yl)isoquinolin-6-           ol       291   3-methyl-7-(6-(piperazin-1-yl)pyridazin-3-yl)isoquinolin-6-ol       292   6-(3-(benzyloxy)isoquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       293   3-chloro-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           7-ol       294   3-isopropyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       295   3-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinoxalin-6-ol       296   4-chloro-2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol       297   4-chloro-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol       300   7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-6-ol       301   5-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       302   6-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)naphthalen-           2-ol       303   5-(2-methoxyquinolin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-           thiadiazol-2-amine       304   5-(3-methoxy-naphthalen-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-           thiadiazol-2-amine       305   5-(2-methoxy-4-(1H-pyrazol-lyl)phenyl)-N-(1,2,2,6,6-pentamethylpiperidin-4-yl)-           1,3,4-thiadiazol-2-amine       306   5-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       307   5-(2-methoxy-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       308   4-(3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       309   5-(3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)pyridin-2-ol       310   5-(3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       311   N-methyl-5-(2-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       312   1-methyl-4-(4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-3-(trifluoromethoxy)phenyl)pyridin-2(1H)-one       313   5-(4-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methoxyphenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       314   N-methyl-5-(4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       315   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl-5-(1-           methyl-1H-pyrazol-4-yl)phenol       316   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl-5-(1H-           pyrazol-1-yl)phenol       317   5-(3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       318   4-(3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       319   5-(3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)pyridin-2-ol       320   3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)naphthalene-2,7-diol       321   3-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,3,4-thiadiazol-2-           yl)naphthalene-2,7-diol           322 1     3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)naphthalen-           2-ol       323   3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)quinolin-2-           ol       324   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-4-(1H-           pyrazol-1-yl)phenol       325   5-(2-chloro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       326   3-chloro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-           5-(1-methyl-1H-pyrazol-4-yl)phenol       327   5-(2-chloro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-           1,3,4-thiadiazol-2-amine       328   3-methoxy-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-5-methyloxazol-2-yl)phenol       329   2-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1,3,4-           thiadiazole       330   2-(5-(piperazin-1-yl)-1,3,4-thiadiazol-2-yl)-5-(1H-pyrazol-1-yl)phenol       331   5-(7-methoxyquinolin-6-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-           thiadiazole-2-amine       332   6-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)quinolin-7-           ol       333   3-methoxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)benzonitrile       334   3-fluoro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)benzonitrile       335   methyl-3-fluoro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-           2-yl)benzoate       336   5-(2-methoxy-4-(3-(methylamino)-1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       337   7-methoxy-6-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)quinoline-2-carbonitrile       338   4-(3-methoxy-4-(5-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       339   4-(3-chloro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)-1-methyipyridin-2(1H)-one       340   5-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       341   5-(2-chloro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)phenyl)-N-methyl-N-           (2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine           342 1     N-methyl-5-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       343   2-(2-chloro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-((2,2,6,6-tetramethylpiperidin-4-           yl)oxy-1,3,4-thiadiazole       344   5-(2-chloro-4-(6-methoxypyridin-3-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       345   5-(4-(6-aminopyridin-3-yl)-2-fluorophenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       346   5-(2-fluoro-4-(3-methyl-1H-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       347   5-(2-fluoro-4-(1H-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       348   5-(2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       349   5-(2,3-difluoro-4-(1H-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       350   5-(2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       351   5-(2,5-difluoro-4-(1H-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       352   5-(2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       353   2-(2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexahydropyrrolo[3,4-           c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       354   5-(2-chloro-5-fluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       355   5-(3-fluoro-5-(1H-pyrazol-4-yl)pyridin-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       356   5-(4-(2-aminopyrimidin-4-yl)-2-chlorophenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       357   5-(5-(2-aminopyrimidin-4-yl)-2-chlorophenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       358   5-(4-(2,4-dimethylthiazol-5-yl)-2,5-difluorophenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       359   5-(4-(2,4-dimethylthiazol-5-yl)-2,3-difluorophenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       360   4-(3-hydroxy-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-5-(trifluoromethoxy)phenyl)-1-methylpyridin-2(1H)-one       361   5-(2-fluoro-6-methoxy-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       362   2-(2-fluoro-6-methoxy-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-           methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       363   5-(2,3-difluoro-6-methoxy-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       364   6-methoxy-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-3,4-dihydroisoquinolin-1-(2H)-one       365   5-(2-chloro-4-(1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       366   5-(2-chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       367   5-(2-chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       368   5-(2-chloro-4-(1H-1,2,4-triazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine       369   5-(4-(3-amino-1H-pyrazol-1-yl)-2-chlorophenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       370   2-(2-chloro-4-(1H-imidazol-1-yl)phenyl)-5-((3aR,6aS)-5-           methylhexahydropyrrolo[3,4c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       371   5-(2-chloro-4-(1H-imidazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       372   5-(2-fluoro-4-(1H-imidazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       373   5-(2-methoxy-4-(1H-pyrazol-5-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       374   5-(4-(2,4-dimethylthiazol-5-yl)-2-methoxyphenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       375   5-(2-methoxy-4-(pyridin-3-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-           1,3,4-thiadiazol-2-amine       376   5-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine       377   5-(2-methoxy-4-(2-methoxypyridin-4-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       378   5-(2-methoxy-4-(6-methoxypyridin-3-yl)phenyl)-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine       379   2-(2-chloro-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-           methylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       380   2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-methylhexahydropyrrolo[3,4-           c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       381   2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aR)-1-methy1Hexahydropyrrolo[3,4-           b]pyrrol-5(1H)-yl)-1,3,4-thiadiazole       382   1-(4-(5-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-1,3,4-thiadiazol-2-yl)morpholin-2-yl)-           N,N-dimethylmethanamine       383   2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-(2-methyl-2,7-diazaspiro[4.5]decan-7-yl)-           1,3,4-thiadiazole       384   2-(2-fluoro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-5-methy1Hexahydropyrrolo[3,4-           c]pyrrol-2(1H)-yl)-1,3,4-thiadiazole       385   2-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-(2,6-diazaspiro[3.5]nonan-2-yl)-           1,3,4-thiadiazole       386   2-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[3.5]nonan-2-yl)-           1,3,4-thiadiazole       387   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-5-(1H-           pyrazol-1-yl)phenol       388   5-(3-chloro-4-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)phenyl)pyridin-2(1H)-one       389   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-5-(3-           (methylamino)-1H-pyrazol-1-yl)phenol       390   3-fluoro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-5-           (1H-pyrazol-4-yl)phenol       391   3,4-difluoro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-5-(1H-pyrazol-4-yl)phenol       392   6-hydroxy-5-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)-2,3-dihydro-1H-inden-1-one       393   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-5-(1H-           pyrazol-4-yl)phenol       394   2-(5-(2,6-diazaspiro[3.5]nonan-2-yl)-1,3,4-thiadiazol-2-yl)-5-(1-methyl-1H-pyrazol-4-           yl)phenol       395   2-(5-(2,7-diazaspiro[3.5]nonan-2-yl)-1,3,4-thiadiazol-2-yl)-5-(1-methyl-1H-pyrazol-4-           yl)phenol           396 1     3-fluoro-2-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,3,4-thiadiazol-2-           yl)-5-(1H-pyrazol-4-yl)phenol       397   3-chloro-2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)-           5-(1H-pyrazol-4-yl)phenol       398   2-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-5-((2,2,6,6-tetramethylpiperidin-4-           yl)methyl)-1,3,4-thiadiazole       399   2-(2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[3.5]nonan-2-yl)-1,3,4-           thiadiazole       400   2-(5-(2,7-diazaspiro[3.5]nonan-2-yl)-1,3,4-thiadiazol-2-yl)-3-fluoro-5-(1H-pyrazol-4-           yl)phenol       401   4-methoxy-l-methyl-3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-           thiadiazol-2-yl)quinolin-2(1H)-one       402   4-hydroxy-1-methyl-3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-           thiadiazol-2-yl)quinolin-2(1H)-one       403   3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)quinolin-           2(1H)-one       404   1-methyl-3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)quinolin-2(1H)-one           405 1     2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl)-1,3,4-thiadiazole           406 1     2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[4.5]decan-2-yl)-1,3,4-           thiadiazole           407 1     (R)-(4-(5-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-1,3,4-thiadiazol-2-yl)piperazin-2-           yl)methanol       408   2-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-           yl)benzo[b]thiophene-5-carbonitrile       409   5-(3-chlorobenzo[b]thiophen-2-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-           1,3,4-thiadiazol-2-amine       410   5-(2-methoxy-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)-1,3,4-thiadiazol-2-amine           411 1     2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-           pyrazol-4-yl)phenol           412 1     2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol           413 1     5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-           yl}phenol       414   5-(1-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol           415 1     2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol       416   5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino]pyridazin-3-yl}phenol       417   5-(1H-imidazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl]phenol       418   5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl]phenol           419 1     2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-           pyrazol-1-yl)phenol       420   6-[2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine       421   5-(4-amino-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl]phenol           422 1     2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol       423   5-(4-nitro-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl]phenol           424 1     5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol           425 1     2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           426 1     2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           427 1     2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           428 1     6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)pyridazin-3-amine           429 1     2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           430 1     6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)pyridazin-3-amine           431 1     3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       432   2-[6-(piperidin-4-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           433 1     2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol           434 1     6-[2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine       435   3-[4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine           436 1     2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           437 1     3-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       438   3-[4-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine           439 1     2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       440   3-fluoro-4-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol       441   2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-1-yl)phenol       442   N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-           3-amine       443   2-methyl-5-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}-2H-indazole       444   3-(4-chloro-2-methoxyphenyl)-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine       445   N-methyl-6-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       446   6-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}imidazo[1,2-a]pyridine       447   3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine           448 1     3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       449   3-[5-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine           450 1     3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       451   5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazin-3-yl}phenol       452   6-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       453   3-methoxy-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol       454   3-[2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       455   4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}benzene-1,3-diol           456 1     6-[2-chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       457   2-(1H-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}pyrimidin-5-amine           458 1     3-[2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       459   2-[6-(2,6-diazaspiro[3.4]oct-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           460 1     3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-           yl)pyridin-2-ol       461   6-(1H-pyrazol-4-yl)-3-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}pyridin-2-ol           462 1     N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-y1)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine           463 1     N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine           464 1     3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine and           465 1     6-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl′)pyridazin-3-amine                    
wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     In one aspect, the compound of Formula (I) or a form thereof includes a compound selected from the group consisting of: 
                                    411 1     2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-           pyrazol-4-yl)phenol       412 1     2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol       413 1     5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-           yl}phenol       414       5-(1-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol       415 1     2-[6-((1R,5S)-8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol       416       5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino]pyridazin-3-yl}phenol       417       5-(1H-imidazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol       418       5-(5-methyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol       419 1     2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-           pyrazol-1-yl)phenol       420       6-[2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine       421       5-(4-amino-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol       422 1     2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-           yl)phenol       423       5-(4-nitro-1H-pyrazol-1-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}phenol       424 1     5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol       425 1     2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       426 1     2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol       427 1     2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       428 1     6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)pyridazin-3-amine       429 1     2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       430 1     6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-           4-yl)pyridazin-3-amine       431 1     3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       432       2-[6-(piperidin-4-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       433 1     2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl}-5-(1H-pyrazol-4-           yl)phenol       434 1     6-[2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine       435       3-[4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine       436 1     2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol       437 1     3-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       438       3-[4-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       439 1     2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       440       3-fluoro-4-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol       441       2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-1-yl)phenol       442       N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-           3-amine       443       2-methyl-5-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}-2H-indazole       444       3-(4-chloro-2-methoxyphenyl)-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazine       445       N-methyl-6-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       446       6-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}imidazo[1,2-a]pyridine       447       3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       448 1     3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       449       3-[5-(1-methyl-1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       450 1     3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       451       5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazin-3-yl}phenol       452       6-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       453       3-methoxy-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol       454       3-[2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       455       4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}benzene-1,3-diol       456 1     6-[2-chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine       457       2-(1H-pyrazol-4-yl)-4-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}pyrimidin-5-amine       458 1     3-[2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine       459       2-[6-(2,6-diazaspiro[3.4]oct-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol       460 1     3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-           yl)pyridin-2-ol       461       6-(1H-pyrazol-4-yl)-3-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-           yl}pyridin-2-ol       462 1     N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine       463 1     N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine       464 1     3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazineand       465 1     6-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine                    
wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     Another embodiment of the use of a compound salt of Formula (I) or a form thereof includes a method of use of a compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject, selected from the group consisting of: 
                                 Cpd   Name                                        32   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (trifluoromethyl)phenol hydrochloride       53   2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-(1H-pyrazol-1-           yl)phenol hydrochloride       65   2-(6-piperazin-1-yl-pyridazin-3-yl)-5-1H-pyrazol-1-yl-phenol hydrochloride       82   3-(6-(piperazin-1-yl)pyridazin-3-yl)naphthalene-2,7-diol trifluoroacetate       86   3-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol trifluoroacetate       88   3-(6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol           trifluoroacetate       89   3-(6-(piperidin-4-yl)pyridazin-3-yl)naphthalene-2,7-diol trifluoroacetate       151   6-hydroxy-5-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-2,3-           dihydro-1H-inden-1-one oxime hydrochloride       153   2-amino-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-8H-           indeno[1,2-d]thiazol-5-ol hydrochloride       154   9-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5,6-           dihydroimidazo[5,1-a] isoquinolin-8-ol hydrochloride       160   3-fluoro-5-(2-methoxypyridin-4-yl)-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-           yl)amino)pyridazin-3-yl)phenol hydrochloride       161   4-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)pyridin-2(1H)-one hydrochloride       162   4-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-1-methylpyridin-2(1H)-one hydrochloride       163   5-(3-fluoro-5-hydroxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenyl)-1-methylpyridin-2(1H)-one hydrochloride       164   3-fluoro-5-(1H-pyrazol-4-yl)-2-(6-((2,2,6,6-tetramethylpiperidin-4-yl)oxy)pyridazin-3-           yl)phenol hydrochloride       165   5-chloro-3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)phenol hydrochloride       166   3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1H-           pyrazol-4-yl)phenol hydrochloride       167   3-fluoro-2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(1-           methyl-1H-pyrazol-4-yl)phenol hydrochloride       226   3-(1H-imidazol-1-yl)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-7-ol hydrochloride       227   6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinoline-3,7-diol           formate       231   7-hydroxy-1-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)quinolin-2(1H)-one hydrochloride       238   4-methoxy-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinolin-           6-ol formate       239   7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)quinoxalin-6-ol           hydrochloride       254   2-methyl-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-4-           (tetrahydro-2H-pyran-4-yl)quinolin-7-ol formate       256   4-(dimethylamino)-6-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-           quinolin-7-ol formate       281   6-hydroxy-2-methyl-7-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-           yl)isoquinolin-1(2H)-one hydrochloride       322   3-(5-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)-1,3,4-thiadiazol-2-yl)naphthalen-           2-ol hydrobromide       342   N-methyl-5-(5-(1-methyl-1H-pyrazol-4-yl)pyridin-2-yl)-N-(2,2,6,6-tetramethylpiperidin-           4-yl)-1,3,4-thiadiazol-2-amine hydrochloride       396   3-fluoro-2-(5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-1,3,4-thiadiazol-2-yl)-           5-(1H-pyrazol-4-yl)phenol dihydrochloride       405   2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-((3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-           2(1H)-yl)-1,3,4-thiadiazole hydrochloride       406   2-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-5-(2,7-diazaspiro[4.5]decan-2-yl)-1,3,4-           thiadiazole hydrochloride       407   (R)-(4-(5-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-1,3,4-thiadiazol-2-yl)piperazin-2-           yl)methanol hydrochloride       411   2-{6-[8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-           yl)phenol hydrochloride       412   2-[6-(8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       413   5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-           yl}phenol hydrochloride       415   2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       419   2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-           pyrazol-1-yl)phenol dihydrochloride       422   2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       424   5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol           trihydrochloride       425   2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       426   2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           tetrahydrochloride       427   2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride       428   6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine tetrahydrochloride       429   2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       430   6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine hydrochloride       431   3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine trihydrochloride       433   2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl}-5-(1H-pyrazol-4-           yl)phenol hydrochloride       434   6-[2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride       436   2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       437   3-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       439   2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           tetrahydrochloride       448   3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       450   3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       456   6-[2-chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine trihydrochloride       458   3-[2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine trihydrochloride       460   3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-           yl)pyridin-2-ol hydrochloride       462   N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine hydrochloride       463   N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine hydrochloride       464   3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride and       465   6-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride                    
wherein a form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     In one aspect, the compound salt of Formula (I) or a form thereof includes a compound salt selected from the group consisting of: 
                                    411   2-{6-[8-azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-           yl)phenol hydrochloride       412   2-[6-(8-azabicyclo[3.2.1]oct-3-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       413   5-(1H-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-           yl}phenol hydrochloride       415   2-[6-(8-azabicyclo[3.2.1]oct-3-yloxy)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       419   2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-           pyrazol-1-yl)phenol dihydrochloride       422   2-[6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       424   5-(1H-pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol           trihydrochloride       425   2-[6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       426   2-{6-[methyl(piperidin-4-yl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           tetrahydrochloride       427   2-[6-(piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride       428   6-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine tetrahydrochloride       429   2-[6-(8-azabicyclo[3.2.1]oct-2-en-3-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           hydrochloride       430   6-[2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine hydrochloride       431   3-[2,5-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine trihydrochloride       433   2-{6-[(1R,5S)-8-azabicyclo[3.2.1]oct-3-ylamino]pyridazin-3-yl}-5-(1H-pyrazol-4-           yl)phenol hydrochloride       434   6-[2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride       436   2-{6-[(2,6-dimethylpiperidin-4-yl)oxy]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol           trihydrochloride       437   3-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       439   2-[6-(2,7-diazaspiro[3.5]non-2-yl)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol           tetrahydrochloride       448   3-[5-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       450   3-[4-(1H-pyrazol-4-yl)thiophen-2-yl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride       456   6-[2-chloro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-           yl)pyridazin-3-amine trihydrochloride       458   3-[2,6-difluoro-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine trihydrochloride       460   3-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-           yl)pyridin-2-ol hydrochloride       462   N,2,2,6,6-pentamethyl-N-{5-[3-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine hydrochloride       463   N,2,2,6,6-pentamethyl-N-{5-[4-(1H-pyrazol-4-yl)phenoxy]-1,3,4-thiadiazol-2-           yl}piperidin-4-amine hydrochloride       464   3-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-6-[(2,2,6,6-tetramethylpiperidin-4-           yl)oxy]pyridazine hydrochloride and       465   6-[2-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-           tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride                    
wherein a form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
 
     Another embodiment of the present description includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     Another embodiment of the present description includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject. 
     Another embodiment of the present description includes a use of the compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     Another embodiment of the present description includes a use of the compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound salt of Formula (I) or a form thereof to the subject. 
     Chemical Definitions 
     As used herein, the term “C 1-4 alkyl” generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration, including, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and the like. In some embodiments, C 1-4 alkyl includes C 1-3 alkyl, C 1-2 alkyl, and the like. A C 1-4 alkyl radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “C 2-6 alkenyl” generally refers to partially unsaturated hydrocarbon radicals having from two to five carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, without limitation, ethenyl, allyl, propenyl and the like. In some embodiments, C 2-6 alkenyl includes C 2-4 alkenyl, C 2-3 alkenyl, and the like. A C 2-6 alkenyl radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “C 1-4 alkoxy” generally refers to saturated hydrocarbon radicals having from one to four carbon atoms in a straight or branched chain configuration of the formula: —O—C 1-4 alkyl, including, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and the like. In some embodiments, C 1-4 alkoxy includes C 1-3 alkoxy, C 1-2 alkoxy and the like. A C 1-4 alkoxy radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “C 3-14 cycloalkyl” generally refers to a saturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl and the like. In some embodiments, C 3-14 cycloalkyl includes C 3-10 cycloalkyl, C 3-8 cycloalkyl, C 3-7 cycloalkyl, C 5-8 cycloalkyl, C 9-10 cycloalkyl and the like. A C 3-14 cycloalkyl radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “C 3-14 cycloalkenyl” generally refers to a partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical having one or more chemically stable carbon-carbon double bonds therein, including, without limitation, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and the like. In some embodiments, C 3-14 cycloalkenyl includes C 3-7 cycloalkenyl, C 3-8 cycloalkenyl, C 5-8 cycloalkenyl, C 3-10 cycloalkenyl and the like. A C 3-14 cycloalkenyl radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “aryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, without limitation, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical may be optionally substituted where allowed by available valences. 
     As used herein, the term “heteroaryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, without limitation, furanyl, thienyl (also referred to as thiophenyl), pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyranyl, thiopyranyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzooxazolyl, 9H-purinyl, quinoxalinyl, isoindolyl, quinolinyl, isoquinolinyl, quinazolinyl, acridinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl, imidazo[5,1-a]isoquinolinyl, 1,4-dihydroindeno[1,2-c]-1H-pyrazolyl, 2,3-dihydro-1H-inden-1-one, 2,3-dihydro-1H-indenyl, 3,4-dihydroquinolin-2(1H)-one, 5,6-dihydroimidazo[5,1-a]isoquinolinyl, 8H-indeno[1,2-d]thiazolyl, benzo[c][1,2,5]oxadiazolyl, benzo[d]oxazol-2(3H)-one, quinolin-2(1H)-one, quinazolin-4-(1H)-one, quinazoline-2,4(1H,3H)-dione, benzo-[d]oxazolyl, pyrazolo[1,5-a]pyridinyl, and the like. A heteroaryl radical may be optionally substituted on a carbon or nitrogen atom ring member where allowed by available valences. 
     As used herein, the term “heterocyclyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, without limitation, oxiranyl, oxetanyl, azetidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, pyrrolinyl, pyrrolidinyl, dihydropyrazolyl, pyrazolinyl, pyrazolidinyl, dihydroimidazolyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, dihydro-2H-pyranyl, dihydro-pyridinyl, tetrahydro-pyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydro-pyridinyl, dihydro-pyrimidinyl, tetrahydro-pyrimidinyl, 1,4,5,6-tetrahydropyrimidinyl, dihydro-pyrazinyl, tetrahydro-pyrazinyl, dihydro-pyridazinyl, tetrahydro-pyridazinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, dihydro-triazinyl, tetrahydro-triazinyl, hexahydro-triazinyl, 1,4-diazepanyl, dihydro-indolyl, indolinyl, tetrahydro-indolyl, dihydro-indazolyl, tetrahydro-indazolyl, dihydro-isoindolyl, dihydro-benzofuranyl, tetrahydro-benzofuranyl, dihydro-benzothienyl, tetrahydro-benzothienyl, dihydro-benzimidazolyl, tetrahydro-benzimidazolyl, dihydro-benzooxazolyl, 2,3-dihydrobenzo[d]oxazolyl, tetrahydro-benzooxazolyl, dihydro-benzooxazinyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, tetrahydro-benzooxazinyl, benzo[1,3]dioxolyl, benzo[1,4]dioxanyl, dihydro-purinyl, tetrahydro-purinyl, dihydro-quinolinyl, tetrahydro-quinolinyl, 1,2,3,4-tetrahydroquinolinyl, dihydro-isoquinolinyl, 3,4-dihydroisoquinolin-(1H)-yl, tetrahydro-isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, dihydro-quinazolinyl, tetrahydro-quinazolinyl, dihydro-quinoxalinyl, tetrahydro-quinoxalinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,3-dioxolanyl, 2,5-dihydro-1H-pyrrolyl, 4,5-dihydro-1H-imidazolyl, tetrahydro-2H-pyranyl, hexahydropyrrolo[3,4-b][1,4]oxazin-(2H)-yl, (4aR,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-(4aH)-yl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, (cis)-octahydrocyclopenta[c]pyrrolyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, 5H-pyrrolo[3,4-b]pyridin-(7H)-yl, 5,7-dihydro-6H-pyrrolo[3,4-b]pyridinyl, tetrahydro-1H-pyrrolo[3,4-b]pyridin-(2H,7H,7aH)-yl, hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, (4aR,7aR)-hexahydro-1H-pyrrolo[3,4-b]pyridin-(2H)-yl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, 2,3,4,9-tetrahydro-1H-carbazolyl, 1,2,3,4-tetrahydropyrazino[1,2-a]indolyl, 2,3-dihydro-1H-pyrrolo[1,2-a]indolyl, (3aR,6aR)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,4R,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,4S,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, (3aR,5r,6aS)-hexahydrocyclopenta[c]pyrrol-(1H)-yl, 1,3-dihydro-2H-isoindolyl, octahydro-2H-isoindolyl, (3aS)-1,3,3a,4,5,6-hexahydro-2H-isoindolyl, (3aR,4R,7aS)-1H-isoindol-(3H,3aH,4H,5H,6H,7H,7aH)-yl, (3aR,7aS)-octahydro-2H-isoindolyl, (3aR,4R,7aS)-octahydro-2H-isoindolyl, (3aR,4S,7aS)-octahydro-2H-isoindolyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2-azabicyclo[2.2.1]heptenyl, 3-azabicyclo[3.1.0]hexanyl, 3,6-diazabicyclo[3.1.0]hexanyl, (1R,5S)-3-azabicyclo[3.1.0]hexanyl, (1S,5R)-3-azabicyclo[3.2.0]heptanyl, 5-azaspiro[2.4]heptanyl, 2,6-diazaspiro[3.3]heptanyl, 2,5-diazaspiro[3.4]octanyl, 2,6-diazaspiro[3.4]octanyl, 2,7-diazaspiro[3.5]nonanyl, 2,7-diazaspiro[4.4]nonanyl, 2-azaspiro[4.5]decanyl, 2,8-diazaspiro[4.5]decanyl, 3,6-diazabicyclo[3.2.1]octyl, 1,4-dihydroindeno[1,2-c]pyrazolyl, dihydropyranyl, dihydropyridinyl, dihydroquinolinyl, 8H-indeno[1,2-d]thiazolyl, tetrahydroimidazo[1,2-a]pyridinyl, pyridin-2(1H)-one, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl and the like. A heterocyclyl radical may be optionally substituted on a carbon or nitrogen atom ring member where allowed by available valences. 
     As used herein, the term “C 2-4 alkenyl-amino-carbonyl” refers to a radical of the formula: —C(═O)—NH—C 2-4 alkenyl. 
     As used herein, the term “C 1-4 alkoxy-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-O—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkoxy-carbonyl” refers to a radical of the formula: —C(═O)—O—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkoxy-carbonyl-amino” refers to a radical of the formula: —NH—C(═O)—O—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkoxy-carbonyl-amino-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-NH—C(═O)—O—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkyl-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkyl-amino” refers to a radical of the formula: —NH—C 1-4 alkyl. 
     As used herein, the term “(C 1-4 alkyl) 2 -amino” refers to a radical of the formula: —N(C 1-4 alkyl) 2 . 
     As used herein, the term “C 1-4 alkyl-amino-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-NH—C 1-4 alkyl. 
     As used herein, the term “(C 1-4 alkyl) 2 -amino-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-N(C 1-4 alkyl) 2 . 
     As used herein, the term “C 1-4 alkyl-amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-NH—C 1-4 alkyl. 
     As used herein, the term “(C 1-4 alkyl) 2 -amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-N(C 1-4 alkyl) 2 . 
     As used herein, the term “C 1-4 alkyl-amino-carbonyl” refers to a radical of the formula: —C(═O)—NH—C 1-4 alkyl. 
     As used herein, the term “(C 1-4 alkyl) 2 -amino-carbonyl” refers to a radical of the formula: —C(═O)—N(C 1-4 alkyl) 2 . 
     As used herein, the term “C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-C(═O)—NH—C 1-4 alkyl. 
     As used herein, the term “(C 1-4 alkyl) 2 -amino-carbonyl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-C(═O)—N(C 1-4 alkyl) 2 . 
     As used herein, the term “C 1-4 alkyl-carbonyl” refers to a radical of the formula: —C(═O)—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkyl-carbonyl-amino” refers to a radical of the formula: —NH—C(═O)—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkyl-carbonyl-amino-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-NH—C(═O)—C 1-4 alkyl. 
     As used herein, the term “C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-NH—C(═O)—C 1-4 alkyl. 
     As used herein, the term “amino” refers to a radical of the formula: —NH 2 . As used herein, the term “amino-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-NH 2 . 
     As used herein, the term “amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-NH 2 . 
     As used herein, the term “amino-carbonyl” refers to a radical of the formula: —C(═O)—NH 2 . 
     As used herein, the term “cyano” refers to a radical of the formula: —CN. 
     As used herein, the term “C 3-7 cycloalkyl-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-C 3-7 cycloalkyl. 
     As used herein, the term “halo-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-halo, wherein C 1-4 alkyl may be partially or completely substituted where allowed by available valences with one or more halogen atoms. In some embodiments, halo-C 1-4 alkoxy includes halo-C 1-6 alkoxy, halo-C 1-4 alkoxy and the like. 
     As used herein, the term “halo-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-halo, wherein C 1-4 alkyl may be partially or completely substituted where allowed by available valences with one or more halogen atoms. In some embodiments, halo-C 1-4 alkyl includes halo-C 1-6 alkyl, halo-C 1-4 alkyl and the like. 
     As used herein, the term “heteroaryl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-4 alkyl-amino” refers to a radical of the formula: —NH—C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-4 alkyl-amino-carbonyl” refers to a radical of the formula: —C(═O)—NH—C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-4 alkyl-amino-carbonyl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-C(═O)—NH—C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-4 alkyl-carbonyl-amino” refers to a radical of the formula: —NH—C(═O)—C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heteroaryl-C 1-4 alkyl-carbonyl-amino-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-NH—C(═O)—C 1-4 alkyl-heteroaryl. 
     As used herein, the term “heterocyclyl-C 1-4 alkoxy” refers to a radical of the formula: —C 1-4 alkoxy-heterocyclyl. 
     As used herein, the term “heterocyclyl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-heterocyclyl. 
     As used herein, the term “hydroxyl” refers to a radical of the formula: —OH. 
     As used herein, the term “hydroxyl-C 1-4 alkoxy” refers to a radical of the formula: —O—C 1-4 alkyl-OH, wherein C 1-4 alkyl may be partially or completely substituted where allowed by available valences with one or more hydroxy radicals. 
     As used herein, the term “hydroxyl-C 1-4 alkyl” refers to a radical of the formula: —C 1-4 alkyl-OH, wherein C 1-4 alkyl may be partially or completely substituted where allowed by available valences with one or more hydroxy radicals. 
     As used herein, the term “hydroxyl-C 1-4 alkyl-amino” refers to a radical of the formula: —NH—C 1-4 alkyl-OH, wherein C 1-4 alkyl may be partially or completely substituted where allowed by available valences with one or more hydroxyl radicals. 
     As used herein, the term “hydroxyl-imino” refers to the ═NOH radical of the formula: C(═NOH). 
     As used herein, the term “oxo” refers to the radical of the formula: C═O. 
     As used herein, the term “phenyl-C 1-4 alkoxy” refers to a radical of the formula: —C 1-4 alkoxy-phenyl. 
     As used herein, the term “substituent” means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom&#39;s normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A person of ordinary skill in the art should note that any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown. In certain instances one or more substituents having a double bond (e.g., “oxo” or “═O”) as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I). A person of ordinary skill in the art would understand that, while only a single bond is shown, a double bond is intended for those substituents. 
     As used herein, the term “and the like,” with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound. 
     For the purposes of this description, where one or more substituent variables for a compound of Formula (I) or a form thereof encompass functionalities incorporated into a compound of Formula (I), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted. 
     As used herein, the terms “independently selected,” or “each selected” refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. Further, the use of a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein. 
     As used herein, the terms “each instance of” or “in each instance, when present,” when used preceding a phrase such as “ . . . C 3-14 cycloalkyl, C 3-14 cycloalkyl-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, heterocyclyl and heterocyclyl-C 1-4 alkyl,” are intended to refer to the C 3-14 cycloalkyl, aryl, heteroaryl and heterocyclyl ring systems when each are present either alone or as a substituent. 
     As used herein, the term “optionally substituted” means optional substitution with the specified substituent variables, groups, radicals or moieties. 
     Compound Forms 
     As used herein, the term “form” means a compound of Formula (I) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is a free acid, free base or salt thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is a salt thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is an isotopologue thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is a tautomer thereof. 
     In certain embodiments described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form. 
     In certain embodiments described herein, the compound of Formula (I) or a form thereof is isolated for use. 
     As used herein, the term “isolated” means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan. 
     As used herein, the term “protected” means that a functional group in a compound of Formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al,  Protective Groups in organic Synthesis  (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. In certain instances, the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotrityl-chloride resin. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. All prodrugs of compounds described herein are included within the scope of the use described herein. 
     As used herein, the term “prodrug” means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. 
     In one example, when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like. In another example, when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof as a prodrug. 
     One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms. 
     As used herein, the term “solvate” means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, “solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. 
     As used herein, the term “hydrate” means a solvate wherein the solvent molecule is water. 
     The compounds of Formula (I) can form salts, which are intended to be included within the scope of this description. Reference to a compound of Formula (I) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. 
     The term “pharmaceutically acceptable salt(s)”, as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization. 
     Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Embodiments of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucaronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. Certain embodiments of acid addition salts include chloride, dichloride, trichloride, bromide, acetate, formate or trifluoroacetate salts. 
     Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.)  Handbook of Pharmaceutical Salts. Properties, Selection and Use . (2002) Zurich: Wiley-VCH; S. Berge et al,  Journal of Pharmaceutical Sciences  (1977) 66(1) 1-19; P. Gould,  International J. of Pharmaceutics  (1986) 33, 201-217; Anderson et al,  The Practice of Medicinal Chemistry  (1996), Academic Press, New York; and in  The Orange Book  (Food &amp; Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto. 
     Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts. 
     All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description. 
     Compounds of Formula (I) and forms thereof, may further exist in a tautomeric form. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein. 
     The compounds of Formula (I) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures. 
     The compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R/S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one embodiment, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another embodiment, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations. 
     As used herein, the term “substantially pure” refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer. 
     In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%. 
     In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%. 
     As used herein, a “racemate” is any mixture of isometric forms that are not “enantiomerically pure”, including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20. 
     In addition, the present description embraces all geometric and positional isomers. For example, if a compound of Formula (I) or a form thereof incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher&#39;s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description. 
     All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra. 
     The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds. 
     The term “isotopologue” refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as  2 H,  3 H,  13 C,  14 C,  15 N,  18 O,  17 O,  31 P,  32 P,  35 S,  18 F,  35 Cl and  36 Cl, respectively, each of which are also within the scope of this description. 
     Certain isotopically-enriched compounds described herein (e.g., those labeled with  3 H and  14 C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e.,  3 H) and carbon-14 (i.e.,  14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e.,  2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. 
     Polymorphic crystalline and amorphous forms of the compounds of Formula (I) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) are further intended to be included in the present description. 
     Compound Uses 
     The present description relates to a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound or a form thereof to the subject. 
     The present description further relates to use of the compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof. 
     The present description further relates to use of the compound of Formula (I) or a form thereof having activity toward HD. 
     The present description further relates to use of the compound of Formula (I) or a form thereof in a combination therapy to provide additive or synergistic activity, thus enabling the development of a combination product for treating or ameliorating HD. 
     In addition to monotherapeutic use, the instant compounds are useful in a combination therapy with current standard of agents, having additive or synergistic activity with one or more known agents. 
     A combination therapy comprising compounds described herein in combination with one or more known drugs may be used to treat HD regardless of whether HD is responsive to the known drug. 
     Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s). 
     Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a combination therapy for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s). 
     In an embodiment of a use or method provided herein, compounds of Formula (I) or a form thereof used in combination with one or more additional agents can be administered to a subject or contacted with a subject or patient cell(s) prior to, concurrently with, or subsequent to administering to the subject or patient or contacting the cell with an additional agent(s). A compound(s) of Formula (I) or a form thereof and an additional agent(s) can be administered to a subject or contacted with a cell in single composition or different compositions. In a specific embodiments, a compound(s) of Formula (I) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, e.g., viral delivery vectors) or the administration of another small molecule HTT inhibitor. In another specific embodiment, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated non-mutant HTT stem cells. In another specific embodiment, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated HTT stem cells. 
     In one embodiment, provided herein is the use of compounds of Formula (I) or a form thereof in combination with supportive standard of care therapies, including palliative care. 
     An embodiment of the present description includes the use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof and an effective amount of one or more agent(s) in a combination therapy for treating or ameliorating HD in a subject in need thereof. 
     Accordingly, the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating HD. In accordance with the use of the present description, compounds that are useful in selectively treating or ameliorating HD, have been identified and use of these compounds for treating or ameliorating HD has been provided. 
     One embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject. 
     One embodiment of the use of the present description relates to a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound to the subject. 
     An embodiment of the use of the present description relates to a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound to the subject. 
     An embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the medicament to the subject. 
     An embodiment of the use of the present description relates to use of a compound of Formula (I) or a form thereof in the preparation of a kit comprising the compound of Formula (I) or a form thereof and instructions for administering the compound for treating or ameliorating HD in a subject in need thereof. 
     In one respect, for each of such embodiments, the subject is treatment naive. In another respect, for each of such embodiments, the subject is not treatment naive. 
     As used herein, the term “treating” refers to: (i) preventing a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition; (ii) inhibiting a disease, disorder or condition, i.e., arresting the development thereof; and/or (iii) relieving a disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition. 
     As used herein, the term “subject” refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food. Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, rattus, canine and feline specie. In some embodiments, the subject is a mammal or a warm-blooded vertebrate animal. In other embodiments, the subject is a human. As used herein, the term “patient” may be used interchangeably with “subject” and “human”. 
     As used herein, the terms “effective amount” or “therapeutically effective amount” mean an amount of compound of Formula (I) or a form, composition or medicament thereof effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof. 
     The dose administered to achieve an effective target plasma concentration may also be administered based upon the weight of the subject or patient. Doses administered on a weight basis may be in the range of about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 40 mg/kg/day, or about 0.001 mg/kg/day to about 30 mg/kg/day, or about 0.001 mg/kg/day to about 20 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 600 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 300 mg/kg/day, or about 0.015 mg/kg/day to about 200 mg/kg/day, or about 0.02 mg/kg/day to about 100 mg/kg/day, or about 0.025 mg/kg/day to about 100 mg/kg/day, or about 0.03 mg/kg/day to about 100 mg/kg/day, wherein said amount is orally administered once (once in approximately a 24 hour period), twice (once in approximately a 12 hour period) or thrice (once in approximately an 8 hour period) daily according to subject weight. 
     In certain embodiments, the effective amount will be in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.1 mg to about 500 mg/kg/day, or about 1.0 mg/day to about 500 mg/kg/day, in single, divided, or a continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg). The typical adult subject is expected to have a median weight in a range of about 70 kg. 
     In another embodiment, where daily doses are adjusted based upon the weight of the subject or patient, compounds described herein may be formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400 or 500 mg/kg/day. Daily doses adjusted based upon the weight of the subject or patient may be administered as a single, divided, or continuous dose. In embodiments where a dose of compound is given more than once per day, the dose may be administered twice, thrice, or more times per day. 
     Within the scope of the present description, the “effective amount” of a compound of Formula (I) or a form thereof for use in the manufacture of a medicament, for use in the preparation of a pharmaceutical kit or in a method of use for treating or ameliorating HD in a subject in need thereof is intended to include an amount in a range of from about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001 mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 40 mg/kg/day, or about 0.001 mg/kg/day to about 30 mg/kg/day, or about 0.001 mg/kg/day to about 20 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 600 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 300 mg/kg/day, or about 0.015 mg/kg/day to about 200 mg/kg/day, or about 0.02 mg/kg/day to about 100 mg/kg/day, or about 0.025 mg/kg/day to about 100 mg/kg/day, or about 0.03 mg/kg/day to about 100 mg/kg/day, wherein said amount is administered once (once in approximately a 24 hour period; i.e., “q.d.”), twice (once in approximately a 12 hour period; i.e., “b.i.d.” or “q.12 h”), thrice (once in approximately an 8 hour period; i.e., “t.i.d.” or “q.8 h”), or four times (once in approximately a 6 hour period; i.e., “q.d.s.”, “q.i.d.” or “q.6 h”) daily according to subject weight. 
     Such amounts may further include an amount in a range of from about 0.001 mg to about 3500 mg administered daily; 0.001 mg to about 3000 mg administered daily; 0.001 mg to about 2500 mg administered daily; 0.001 mg to about 2000 mg administered daily; 0.001 mg to about 1500 mg administered daily; 0.001 mg to about 1000 mg administered daily; 0.001 mg to about 500 mg administered daily; 0.001 mg to about 250 mg administered daily; 1.0 mg to about 3500 mg administered daily; 1.0 mg to about 1500 mg administered daily; 1.0 mg to about 1000 mg administered daily; 10.0 mg to about 600 mg administered daily; 0.5 mg to about 2000 mg administered daily; or, an amount in a range of from about 5.0 mg to about 300 mg administered daily. 
     For example, the effective amount may be the amount required to treat HD in a subject or, more specifically, in a human. The effective amount for a subject will depend upon various factors, including the subject&#39;s body weight, size and health. Effective amounts for a given patient can be determined by routine experimentation that is within the skill and judgment of the clinician. 
     For any compound, the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50  (the dose therapeutically effective in 50% of the population) and LD 50  (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD 50 /ED 50 . In some embodiments, the effective amount is such that a large therapeutic index is achieved. In further embodiments, the dosage is within a range of circulating concentrations that include an ED 50  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. 
     More specifically, the concentration-biological effect relationships observed with regard to a compound of Formula (I) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 μg/mL to approximately 50 μg/mL, from approximately 0.01 μg/mL to approximately 20 μg/mL, from approximately 0.05 μg/mL to approximately 10 μg/mL, or from approximately 0.1 μg/mL to approximately 5 μg/mL. To achieve such plasma concentrations, the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 0.1 ng to 10,000 mg, depending upon the route of administration in single, divided, or continuous doses for a patient weighing between about 10 to about 100 kg (which dose may be adjusted for patients within this weight range, particularly for children under 40 kg). 
     The exact dosage will be determined by the practitioner, in light of factors related to the subject. Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, ethnicity, age, weight, gender, diet, time of day and frequency of administration, drug combination(s), reaction sensitivities, experience with other therapies, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation. 
     The compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art. Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intravenous (bolus and infusion), intracerebral, and pulmonary routes of administration. 
     In one aspect, provided herein are methods for modulating the amount of HTT (huntingtin protein), comprising contacting a human cell with a compound of Formula (I) or a form thereof. In a specific embodiment, provided herein are methods for modulating the amount of HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof that modulates the expression of HTT. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific embodiment, the human cell is from or in a human. In another specific embodiment, the human cell is from or in a human with HD. In another specific embodiment, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human with HD. In one embodiment, the compound is a form of the compound of Formula (I). 
     In a specific embodiment, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, comprising contacting a human cell with a compound of Formula (I) or a form thereof. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific embodiment, the human cell is from or in a human. In another specific embodiment, the human cell is from or in a human with HD. In another specific embodiment, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of wild-type “normal” HTT expression and/or function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human with HD. In one embodiment, the compound is a form of the compound of Formula (I). 
     In another aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific embodiment, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific embodiment, the compound is a form of the compound of Formula (I). 
     In another aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof. In a specific embodiment, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) that inhibits the transcription of mutant HTT (huntingtin mRNA) from the Htt gene. In another specific embodiment, provided herein is a method for decreasing the amount of HTT, comprising contacting a human cell with a compound of Formula (I) that inhibits the expression of mutant HTT transcribed from the Htt gene. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific embodiment, the human cell is from or in a human. In another specific embodiment, the human cell is from or in a human with HD. In another specific embodiment, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another embodiment, the human cell is from a human with HD. In another embodiment, the human cell is in a human with HD. In one embodiment, the compound is a form of the compound of Formula (I). 
     In certain embodiments, treating or ameliorating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and/or beneficial effect. In a specific embodiment, treating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) results in one, two or more of the following effects: (i) reduces or ameliorates the severity of HD; (ii) delays onset of HD; (iii) inhibits the progression of HD; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life for a subject; (viii) reduces the number of symptoms associated with HD; (ix) reduces or ameliorates the severity of a symptom(s) associated with HD; (x) reduces the duration of a symptom associated with HD; (xi) prevents the recurrence of a symptom associated with HD; (xii) inhibits the development or onset of a symptom of HD; and/or (xiii) inhibits of the progression of a symptom associated with HD. 
     Metabolites of the Compounds 
     Also included within the scope of the present description are the use of in vivo metabolic products of the compounds described herein. Such products may result, for example, from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof. 
     Such products typically are identified by preparing a radio-labeled isotopologue (e.g.,  14 C or  3 H) of a compound described herein, administering the radio-labeled compound in a detectable dose (e.g., greater than about 0.5 mg/kg) to a mammal such as a rat, mouse, guinea pig, dog, monkey or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products from urine, bile, blood or other biological samples. The conversion products are easily isolated since they are “radiolabeled” by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites may be done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found in vivo, are useful in diagnostic assays for therapeutic dosing of the compounds described herein even if they possess no biological activity of their own. 
     Pharmaceutical Compositions 
     Embodiments of the present description include the use of a compound of Formula (I) or a form thereof in a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s). 
     An embodiment of the present description includes the use of a pharmaceutical composition of the compound of Formula (I) or a form thereof in the preparation of a kit comprising the pharmaceutical composition of the compound of Formula (I) or a form thereof and instructions for administering the compound for treating or ameliorating HD in a subject in need thereof. 
     As used herein, the term “composition” means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. 
     The pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In some embodiments, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other embodiments, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8. 
     The term “pharmaceutically acceptable excipient” refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein. The term refers to any pharmaceutical excipient that may be administered without undue toxicity. Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of administration and/or dosage form. Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compounds described herein (see, e.g., Remington&#39;s Pharmaceutical Sciences). 
     Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like. Liposomes are also included within the definition of pharmaceutically acceptable excipients. 
     The pharmaceutical compositions described herein may be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration. 
     When intended for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a palatable preparation. 
     Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross-linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed. 
     Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil. 
     In other embodiments, pharmaceutical compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipient(s) suitable for the manufacture of a suspension. In yet other embodiments, pharmaceutical compositions described herein may be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipient(s). 
     Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcelluose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin. 
     The pharmaceutical compositions described herein may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent. 
     Additionally, the pharmaceutical compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension. Such emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer&#39;s solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables. 
     The compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g., caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids. Thus, contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc. 
     In some embodiments, the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds. Lipid-based formulations can generally enhance the oral bioavailability of such compounds. As such, pharmaceutical compositions described herein may comprise a effective amount of a compound of Formula (I) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween® 20 or Tween®80, respectively) or polyoxyl 40 hydrogenated castor oil. 
     In other embodiments, the bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms. 
     In alternative embodiments, the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin. Nonlimiting examples of cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of α-, β-, and γ-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPBC). In some embodiments, the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%. The amount of solubility enhancer employed may depend on the amount of the compound in the composition. 
     Preparation of Compounds 
     Compounds provided herein can be prepared by those skilled in the art, such as, by the synthetic methods set forth in International Application Publication Number WO2014/028459 A1, published Feb. 20, 2014, International Application Publication Number WO2014/116845 A1, published Jul. 31, 2014, and International Application Publication Number WO2015/017589 A1, published Feb. 5, 2015, each of which are herein incorporated by reference. 
     General Schemes 
     The following reaction schemes illustrate methods to make compounds described herein. It is understood that one skilled in the art would be able to make these compounds by similar methods or by methods known to one skilled in the art. 
     In general, starting components and reagents may be commercially obtained from various sources such as commercial vendors, synthesized according to methodology known to those skilled in the art, or prepared as described herein. It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds. 
     In general, compounds of Formula (I) described herein can be synthesized following the general procedure for Scheme 1. 
                         
General Procedure for Scheme 1
 
     The starting materials for the above reaction scheme are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein. In general, the compounds described herein are prepared in the above reaction Scheme 1 as follows: a halogenated Compound 1a (wherein Hal is a halogen selected from bromine or chlorine) is reacted with a Compound 1b (wherein H is a reactive hydrogen atom in an amine or alcohol X functional group, wherein X and B for a compound of Formula (I) are as described herein) using a displacement or a metal-mediated cross coupling reaction, such as a Buchwald reaction, to provide an intermediate Compound 1c. Compound 1c is carried forward and reacted with a boronate acid or boronate ester Compound Id (where B represents a boron atom, R represents a an acid or ester functional group or, when taken together with boron, form a ring system and A for a compound of Formula (I) is as described herein) using a transition metal-mediated cross coupling reaction, such as a Suzuki reaction, to provide a Compound of Formula (I). 
     In a complementary manner, compounds of Formula (I) may also be synthesized in reverse order wherein the boronate Compound Id is reacted first with Compound 1a followed by reaction of the intermediate with amine Compound 1b. Other variations representing different combinations for substituting either or both boronate Compound Id and amine Compound 1b on Compound 1a are intended to be included within the scope of the synthetic methodologies described herein. 
     SPECIFIC EXAMPLES 
     To assist in understanding the present description, the following specific examples are included. The experiments relating to this description should not, of course, be construed as specifically limiting the description and such variations of the description, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the description as described herein and hereinafter claimed. 
     Other than in the working examples, unless indicated to the contrary, all numbers expressing quantities of materials, reagents, reaction conditions, experimental data, and so forth used in the specification and claims are to be understood as being modified by the term “about”. Accordingly, all such numbers represent approximations that may vary depending upon the desired properties sought to be obtained by a reaction or as a result of variable experimental conditions. Therefore, within an expected range of experimental reproducibility, the term “about” in the context of the resulting data, refers to a range for data provided that may vary according to a standard deviation from the mean. As well, for experimental results provided, the resulting data may be rounded up or down to present data consistently, without loss of significant figures. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding techniques. 
     While the numerical ranges and parameters setting forth the broad scope of the description are approximations, the numerical values set forth in the working examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. 
     The column chromatography system used for product purification was an ISCO CombiFlash™ brand chromatography system (manufactured by Teledyne Isco). 
     SYNTHETIC EXAMPLES 
     Greater details of the present description are provided with reference to the following non-limiting examples, which are offered to more fully illustrate the description, but are not to be construed as limiting the scope thereof. The examples illustrate the preparation of certain compounds described herein, and the testing of these compounds in vitro and/or in vivo. Those of skill in the art will understand that the techniques described in these examples represent techniques described by the inventors to function well in the practice of the description, and as such constitute preferred modes for the practice thereof. However, those of skill in the art should appreciate in light of the present disclosure that many changes can be made to the specific methods that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the description. 
     As used above, and throughout this description, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings: 
     
       
         
           
               
               
             
               
                   
               
               
                 Abbreviation 
                 Meaning 
               
               
                   
               
             
            
               
                 AcOH or HOAc 
                 acetic acid 
               
               
                 ACN or MeCN 
                 acetonitrile 
               
               
                 Bn 
                 benzyl 
               
               
                 BnBr 
                 benzyl bromide 
               
               
                 BnO or OBn 
                 benzyloxy 
               
               
                 Boc 
                 tert-butoxycarbonyl 
               
               
                 Boc 2 O or (Boc) 2 O 
                 di-tert-butyl dicarbonate 
               
               
                 tBuXPhos-Pd-G3 
                 [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)- 
               
               
                   
                 2-(2′-amino-1,1′-biphenyl)] palladium(II) methanesulfonate 
               
               
                 Cbz 
                 benzyloxycarbonyl 
               
               
                 DCE 
                 dichloroethane 
               
               
                 DCM 
                 dichloromethane (CH 2 Cl 2 ) 
               
               
                 DIBAL-H 
                 diisobutylaluminium hydride 
               
               
                 DIPEA 
                 N,N-diisopropylethylamine 
               
               
                 DMF 
                 dimethyl formamide 
               
               
                 DMA 
                 dimethylacetamide 
               
               
                 DMAP 
                 4-dimethylaminopyridine 
               
               
                 DMB 
                 2,4-dimethoxybenzyl 
               
               
                 DMSO 
                 dimethylsulfoxide 
               
               
                 EA or EtOAc 
                 ethyl acetate 
               
               
                 EtOH 
                 ethanol 
               
               
                 Et 2 O 
                 diethyl ether 
               
               
                 HCl 
                 hydrochloric acid 
               
               
                 HPLC 
                 high performance liquid chromatography 
               
               
                 h/hr/hrs/min/s 
                 hour(s)(h, hr or hrs)/minute(s)(min/mins)/second(s) 
               
               
                 K 2 CO 3   
                 potassium carbonate 
               
               
                 KOAc 
                 potassium acetate 
               
               
                 K 3 PO 4   
                 potassium phosphate 
               
               
                 LAH 
                 lithium aluminium hydride 
               
               
                 LC/MS, LCMS or LC-MS 
                 liquid chromatographic mass spectroscopy 
               
               
                 LDA 
                 lithium diisopropylamide 
               
               
                 LiHMDS 
                 lithium bis(trimethylsilyl)amide 
               
               
                 Me 4 tBu-XPhos 
                 di-tert-butyl(2′,4′,6′-triisopropyl-3,4,5,6-tetramethyl-[1,1′- 
               
               
                   
                 biphenyl]-2-yl)phosphine 
               
               
                 MeI 
                 methyl iodide 
               
               
                 MeOH 
                 methanol 
               
               
                 Me 2 NH or NHMe 2   
                 dimethyl amine 
               
               
                 MS 
                 mass spectroscopy 
               
               
                 N 2   
                 nitrogen 
               
               
                 Na 2 SO 4   
                 sodium sulfate 
               
               
                 NaBH(OAc) 3   
                 sodium triacetoxyborohydride 
               
               
                 NaHMDS 
                 sodium bis(trimethylsilyl)amide 
               
               
                 NBS 
                 N-bromosuccinimide 
               
               
                 NH 4 OH 
                 ammonium hydroxide 
               
               
                 NMO 
                 N-methylmorpholine-N-oxide 
               
               
                 NMP 
                 N-methyl-2-pyrrolidone 
               
               
                 n-BuLi 
                 n-butyl lithium 
               
               
                 NMR 
                 nuclear magnetic resonance 
               
               
                 Pd/C 
                 palladium on carbon 
               
               
                 Pd 2 (dba) 3   
                 tris(dibenzylideneacetone)dipalladium(0) 
               
               
                 Pd(dppf)Cl 2   
                 [1,1′-bis(diphenylphosphino)ferrocene] dichloropalladium(II) 
               
               
                 Pd(PPh 3 ) 4   
                 tetrakis(triphenylphosphine)palladium 
               
               
                 Pin 
                 pinacol 
               
               
                 psi 
                 pounds per square inch pressure 
               
               
                 S-Phos 
                 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl 
               
               
                 TBDPSCl 
                 tert-butyldiphenylchlorosilane 
               
               
                 TBS 
                 tert-butyldimethylsilyl 
               
               
                 TBSCl 
                 tert-butyldimethylsilyl chloride 
               
               
                 t-BuOK 
                 potassium tert-butoxide 
               
               
                 TEA or NEt 3   
                 triethylamine 
               
               
                 TFA 
                 trifluoroacetic acid 
               
               
                 THF 
                 tetrahydrofuran 
               
               
                 THP 
                 tetrahydro-2H-pyranyl 
               
               
                 THPO or OTHP 
                 tetrahydro-2H-pyran-2-yl-oxy 
               
               
                 TIPS-H or TIPSH 
                 triisopropyl silane 
               
               
                 TEC 
                 thin layer chromatography 
               
               
                 TMP 
                 2,2,6,6-tetramethylpiperidinyl 
               
               
                 TMPMgCl—LiCl 
                 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium 
               
               
                   
                 chloride 
               
               
                 TMSI 
                 trimethylsilyl iodide 
               
               
                 TMSOK 
                 potassium trimethylsilanolate 
               
               
                   
               
            
           
         
       
     
     Example 1 (Compound 411) 
     2-{6-[8-Azabicyclo[3.2.1]oct-3-yl(methyl)amino]pyridazin-3-yl}-5-(1H-pyrazol-4-yl)phenol hydrochloride 
     Step 1: 3,6-Dibromopyridazine (133.7 mg, 0.56 mmol), tert-butyl (1R,5S)-3-(methylamino)-8-azabicyclo[3.2.1]octane-8-carboxylate (85 mg, 0.28 mmol) and DIPEA (0.15 mL, 0.84 mmol) were mixed in 1 mL of ACN and heated to 100° C. for 1 h until LC-MS showed complete consumption of the starting material. The reaction mixture was concentrated and purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 30% MeOH), column: silica 4 g to afford tert-butyl (1S,5R)-3-[(6-bromopyridazin-3-yl)-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (55 mg, 49.25% yield). 
     Step 2: tert-Butyl 3-[(6-bromopyridazin-3-yl)-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (55 mg, 0.14 mmol), 4-[3-(methoxymethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (68.82 mg, 0.17 mmol), Pd(dppf)Cl 2  (10.34 mg, 0.01 mmol), K 2 CO 3  (57.98 mg, 0.42 mmol) were mixed in a Schlenk tube. The reaction was degassed with N 2  for 15 min and dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , concentrated under vacuum, purified via column chromatography: eluting with gradient CH 2 Cl 2 /EtOAc (0% to 80%), column: silica 4 g, to provide tert-butyl (1S,5R)-3-[[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]pyridazin-3-yl]-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (52 mg, 62%) as a tan solid. 
     Step 3: To a solution of tert-butyl (1S,5R)-3-[[6-[2-(methoxymethoxy)-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]pyridazin-3-yl]-methyl-amino]-8-azabicyclo[3.2.1]octane-8-carboxylate (52 mg, 0.086 mmol) in a 1 mL mixture of CH 2 Cl 2  and 0.5 mL of MeOH was added HCl (4 mol/L) in 1,4-dioxane (0.06 mL). The reaction was stirred overnight. The precipitate was filtered, then dried under vacuum to provide 2-[6-[8-azabicyclo[3.2.1]octan-3-yl(methyl)amino]pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol; hydrochloride (15 mg, 42.25% yield) as a yellow solid. 
     LC-MS: 377 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.37-9.51 (m, 1H), 8.87-8.96 (m, 1H), 8.31 (d, J=9.8 Hz, 1H), 8.12 (s, 2H), 7.74 (d, J=8.2 Hz, 2H), 7.19-7.27 (m, 2H), 4.80-4.92 (m, 1H), 4.08-4.14 (m, 3H), 3.07 (s, 3H), 2.30 (td, J=12.6, 2.8 Hz, 2H), 1.99-2.15 (m, 4H), 1.74-1.87 (m, 2H) 
     Using the procedure described for Example 1 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 412 
                 LC-MS: 363 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.24-9.34 (m, 1H), 9.09- 
               
               
                   
                 9.21 (m, 1H), 8.30 (d, J = 9.8 Hz, 1H), 8.09 (s, 2H), 7.64-7.67 (m, 1H), 7.63 (d, J = 8.2 
               
               
                   
                 Hz, 1H), 7.25-7.27 (m, 1H), 7.24 (s, 1H), 5.42 (br s, 2H), 4.23-4.31 (m, 1H), 4.00- 
               
               
                   
                 4.13 (m, 2H), 2.17 (s, 4H), 1.97-2.02 (m, 2H), 1.94 (td, J = 12.6, 2.5 Hz, 2H) 
               
               
                 413 
                 LC-MS: 393 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.34-9.49 (m, 1H), 8.43- 
               
               
                   
                 8.56 (m, 1H), 8.30 (d, J = 9.8 Hz, 1H), 8.10 (s, 2H), 7.63 (s, 2H), 7.19-7.30 (m, 2H), 
               
               
                   
                 5.77 (br s, 2H), 4.41-4.62 (m, 1H), 2.08 (dd, J = 11.7, 2.8 Hz, 2H), 1.72 (td, J = 12.1, 
               
               
                   
                 2.8 Hz, 2H), 1.53 (s, 6H), 1.49 (s, 6H) 
               
               
                 415 
                 LC-MS: 364 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.61 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 8.24 (s, 2H), 7.85 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 9.5 Hz, 1H), 7.38 (dd, J = 8.2, 1.6 Hz, 
               
               
                   
                 1H), 7.32 (d, J = 1.6 Hz, 1H), 5.65 (spt, J = 5.7 Hz, 1H), 4.25 (dd, J = 3.6, 2.8 Hz, 2H), 
               
               
                   
                 4.17-4.32 (m, 2H), 2.24 (s, 4H), 2.11 (tt, J = 11.2, 2.8 Hz, 2H) (3 hydrogens 
               
               
                   
                 corresponding to OH and NH unobserved) 
               
               
                 433 
                 LC-MS: 363 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.42 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 8.34 (s, 2H), 7.80 (d, J = 9.8 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.40 (dd, J = 8.2, 2.5 
               
               
                   
                 Hz, 1H), 7.32 (d, J = 1.6 Hz, 1H), 4.18 (td, J = 6.9, 0.9 Hz, 1H), 4.11-4.16 (m, 2H), 
               
               
                   
                 2.42-2.52 (m, 4H), 2.32-2.35 (m, 1H), 2.28-2.32 (m, 1H), 2.15-2.25 (m, 2H), (4 
               
               
                   
                 hydrogens corresponding to OH and NH unobserved) 
               
               
                   
               
            
           
         
       
     
     Example 2 (Compound 416) 
     5-(5-Methyl-1H-pyrazol-4-yl)-2-{6-[methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}phenol 
     Step 1: 3-Methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl trifluoromethanesulfonate (80 mg, 0.16 mmol), (tert-butyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (59 mg, 0.19 mmol), Pd(dppf)Cl 2  (7 mg, 0.01 mmol), K 2 CO 3  (66 mg, 0.48 mmol) were mixed in a Schlenk tube. The reaction was degassed with N 2  for 15 min and dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , concentrated under vacuum, then purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 30% MeOH), column: silica 4 g to provide tert-butyl 4-(3-methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl)-3-methyl-1H-pyrazole-1-carboxylate (46 mg, 54%) as light brown solid. 
     Step 2: A solution of tert-butyl 4-(3-methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl)-3-methyl-1H-pyrazole-1-carboxylate (46 mg, 0.09 mmol) in 2 mL of dry CH 2 Cl 2  was cooled in ice-water bath. Boron tribromide 1.0 M in CH 2 Cl 2  (0.45 mL, 0.45 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2 mL of MeOH, stirred for 30 min, then concentrated and purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (2.5% NH 4 OH) (0% to 30% MeOH/NH 4 OH), column: silica 4 g, to provide tert-butyl 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(3-methyl-1H-pyrazol-4-yl)phenol (20 mg, 55%) as a yellow solid. 
     LC-MS: 421 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 13.74 (s, 1H), 12.63-12.71 (m, 1H), 8.20 (d, J=9.5 Hz, 1H), 8.03-8.04 (m, 1H), 7.86 (d, J=8.0 Hz, 1H), 7.73-7.75 (m, 1H), 7.36 (d, J=9.5 Hz, 1H), 7.03-7.06 (m, 2H), 4.90-5.05 (m, 1H), 2.92 (s, 3H), 2.43 (s, 3H), 1.43-1.54 (m, 2H), 1.15-1.43 (m, 2H), 1.14 (s, 6H), 1.09 (s, 6H) 
     Using the procedure described for Example 2 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 414 
                 LC-MS: 408 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 13.84 (s, 1H), 8.10-8.29 
               
               
                   
                 (m, 2H), 7.92 (s, 1H), 7.84 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 9.8 Hz, 1H), 7.08-7.19 (m, 
               
               
                   
                 2H), 4.87-5.03 (m, 1H), 3.87 (s, 3H), 2.96 (s, 3H), 1.48-1.59 (m, 2H), 1.38-1.48 (m, 
               
               
                   
                 2H), 1.26 (s, 6H), 1.09 (s, 6H) 
               
               
                 418 
                 LC-MS: 422 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 12.89 (s, 1H), 12.29-12.48 
               
               
                   
                 (m, 1H), 8.41 (dd, J = 8.8, 0.9 Hz, 1H), 7.95 (dd, J = 7.9, 0.9 Hz, 1H), 7.37 (dd, J = 9.1, 
               
               
                   
                 1.3 Hz, 1H), 6.85-6.94 (m, 2H), 5.61-5.70 (m, 1H), 2.25 (br s., 6H), 2.09 (dd, 
               
               
                   
                 J = 11.8, 3.9 Hz, 2H), 1.25-1.33 (m, 2H), 1.24 (s, 6H), 1.11 (s, 6H), (1 hydrogen 
               
               
                   
                 corresponding to OH or NH unobserved) 
               
               
                 451 
                 LC-MS: 408 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 13.00 (s, 1H), 12.59-12.80 
               
               
                   
                 (m, 1H), 8.42 (d, J = 9.5 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.38 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 7.03-7.18 (m, 2H), 5.55-5.78 (m, 1H), 2.39 (br s., 3H), 2.03-2.13 (m, 2H), 1.26-1.41 
               
               
                   
                 (m, 2H), 1.24 (s, 6H), 1.11 (s, 6H), (1 hydrogen corresponding to OH or NH 
               
               
                   
                 unobserved) 
               
               
                   
               
            
           
         
       
     
     Example 3 (Compound 419) 
     2-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-5-(4-nitro-1H-pyrazol-1-yl)phenol dihydrochloride 
     Step 1: 3-Methoxy-4-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)phenyl trifluoromethanesulfonate (335 mg, 0.67 mmol), 4-nitro-1H-pyrazole (340 mg, 4.5 mmol), Pd 2 (dba) 3  (67 mg, 0.07 mmol), Me 4 tBu-XPhos (35 mg, 0.07 mmol), K 3 PO 4  (368 mg, 1.73 mmol) were mixed in a Schlenk tube. The reaction was degassed with N 2  for 15 min and dioxane (8 mL) was added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, filtered through celite, concentrated, purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 30% MeOH), column: silica 12 g, to provide 6-(2-methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (202 mg, 65%). 
     LC-MS: 466 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.81-9.85 (m, 1H), 8.61 (d, J=0.6 Hz, 1H), 7.91 (d, J=8.5 Hz, 1H), 7.81 (d, J=9.8 Hz, 1H), 7.73 (d, J=1.9 Hz, 1H), 7.68 (dd, J=8.2, 2.2 Hz, 1H), 7.10-7.21 (m, 1H), 5.08-5.26 (m, 1H), 3.96 (s, 3H), 2.95 (s, 3H), 1.59-1.75 (m, 4H), 1.40 (s, 6H), 1.33, (s, 6H), ( 1  hydrogen corresponding to OH or NH unobserved) 
     Step 2: 6-(2-Methoxy-4-(4-nitro-1H-pyrazol-1-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (150 mg, 0.32 mmol), benzenethiol (33 μL, 0.32 mmol) and K 2 CO 3  (44 mg, 0.32 mmol) were mixed in a microwave tube. The reaction was degassed with N 2  for 15 min and dry NMP (1.5 mL) was added. The reaction was heated in a Biotage microwave at 190° C. for 20 min, then diluted with 10 mL EtOAc, and washed with water and brine. The product was dried over Na 2 SO 4 , concentrated under vacuum, then purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 30% MeOH), column: silica 4 g, to provide 2-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-5-(4-nitro-1H-pyrazol-1-yl)phenol (60 mg, 42%) as a brown solid. 
     LC-MS: 452 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.77 (s, 1H), 8.68 (d, J=9.8 Hz, 1H), 8.62 (s, 1H), 8.27 (d, J=8.8 Hz, 1H), 7.87-7.94 (m, 1H), 7.66 (dd, J=8.5, 2.6 Hz, 1H), 7.64 (d, J=2.6 Hz, 1H), 5.03-5.22 (m, 1H), 3.01 (s, 3H), 1.84-1.94 (m, 2H), 1.70-1.77 (m, 2H), 1.53 (s, 6H), 1.43 (s, 6H), (2 hydrogens corresponding to OH and NH unobserved) 
     Using the procedure described for Example 3 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 417 
                 LC-MS: 394 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 13.49 (br s, 1H), 8.49 (d, 
               
               
                   
                 J = 9.8 Hz, 1H), 8.39 (s, 1H), 8.10 (d, J = 8.8 Hz, 1H), 7.79-7.92 (m, 1H), 7.43 (d, 
               
               
                   
                 J = 9.5 Hz, 1H), 7.34 (d, J = 2.5 Hz, 1H), 7.30 (dd, J = 8.5, 2.5 Hz, 1H), 7.12 (s, 1H), 
               
               
                   
                 5.61-5.71 (m, 1H), 2.09 (dd, J = 12.0, 3.8 Hz, 2H), 1.25-1.32 (m, 2H), 1.24 (s, 6H), 
               
               
                   
                 1.11 (s, 6H), (1 hydrogen corresponding to OH or NH unobserved) 
               
               
                 421 
                 LC-MS: 409 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.31 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 7.92 (d, J = 9.1 Hz, 1H), 7.79 (d, J = 0.6 Hz, 1H), 7.44 (d, J = 0.9 Hz, 1H), 7.24-7.33 
               
               
                   
                 (m, 3H), 5.77 (tt, J = 11.2, 4.1 Hz, 1H), 2.28 (dd, J = 12.3, 4.2 Hz, 2H), 1.49 (t, J = 12.3 
               
               
                   
                 Hz, 2H), 1.42 (s, 6H), 1.30 (s, 6H), (4 hydrogens corresponding to OH and NH 
               
               
                   
                 unobserved) 
               
               
                 423 
                 LC-MS: 439 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.71 (d, J = 0.6 Hz, 1H), 
               
               
                   
                 8.58 (d, J = 0.6 Hz, 1H), 8.47 (d, J = 9.5 Hz, 1H), 8.14 (d, J = 8.5 Hz, 1H), 7.59-7.64 
               
               
                   
                 (m, 2H), 7.44 (d, J = 9.5 Hz, 1H), 5.67-5.73 (m, 1H), 2.18-2.28 (m, 2H), 1.45-1.56 
               
               
                   
                 (m, 2H), 1.37 (s, 6H), 1.27 (s, 6H),), (2 hydrogens corresponding to OH and NH 
               
               
                   
                 unobserved) 
               
               
                   
               
            
           
         
       
     
     Example 4 (Compound 424) 
     5-(1H-Pyrazol-4-yl)-2-[6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl]phenol trihydrochloride 
     Step 1: 3-Bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (100 mg, 0.24 mmol), (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid (66 mg, 0.29 mmol), PddppfCl 2  (8 mg, 0.012 mmol), K 2 CO 3  (99 mg, 0.72 mmol) were mixed in a Schlenk tube. The reaction was degassed with N 2  for 15 min and dioxane (2 mL) and water (0.5 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, and partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , then concentrated under vacuum, and purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 20% MeOH), column: silica 4 g, to provide 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)phenol (102 mg, 82%) as an off-white solid. 
     Step 2: A solution of 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)phenol (102 mg, 0.196 mmol) in 2 mL of dry CH 2 Cl 2  was cooled in ice-water bath. Boron tribromide 1.0 M in CH 2 Cl 2  (0.98 mL, 0.98 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2 mL of MeOH, stirred for 30 min, then concentrated and purified using preparative HPLC to provide 5-(1H-pyrazol-4-yl)-2-(6-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3-yl)phenol (41 mg, 66%) as an off-white solid. 
     LC-MS: 320 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.19 (br S, 2H), 8.54 (d, J=9.6 Hz, 1H), 8.22, (d, J=9.6 Hz, 1H), 8.18 (s, 1H), 8.05 (d, J=8.8 Hz, 1H), 7.25-7.29 (m, 2H), 6.92 (s, 1H), 3.85-3.92 (m, 2H), 3.38-3.41 (m, 2H), 2.88-2.98 (m, 2H), ( 1  hydrogen corresponding to OH or NH unobserved) 
     Using the procedure described for Example 4 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 422 
                 LC-MS: 334 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 11.06 (br s, 1H), 8.56 (d, 
               
               
                   
                 J = 9.2 Hz, 1H), 8.25 (d, J = 9.2 Hz, 1H), 8.20 (s, 2H), 8.05 (d, J = 8.8 Hz, 1H), 7.22-7.31 
               
               
                   
                 (m, 2H), 6.92 (s, 1H), 4.06-4.12 (m, 1H), 3.87-3.94 (m, 1H), 3.62-3.70 (m, 1H), 
               
               
                   
                 3.21-3.30 (m, 1H), 3.07-3.12 (m, 2H), 3.03 (s, 3H), (1 hydrogen corresponding to 
               
               
                   
                 OH or NH unobserved) 
               
               
                 425 
                 LC-MS: 348 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 10.94 (br S, 1H), 8.56 (d, 
               
               
                   
                 J = 9.6 Hz, 1H), 8.26 (d, J = 9.6 Hz, 1H), 8.19-8.23 (m, 2H), 8.05 (d, J = 8.4 Hz, 1H), 
               
               
                   
                 7.26-7.31 (m, 2H), 6.93 (s, 1H), 4.07-4.13 (m, 1H), 3.85-3.91 (m, 1H), 3.70-3.74 
               
               
                   
                 (m, 1H), 3.22-3.30 (m, 3H), 3.08-3.14 (m, 2H), 1.33 (t, J = 7.2Hz, 3H), (1 hydrogen 
               
               
                   
                 corresponding to OH or NH unobserved) 
               
               
                 429 
                 LC-MS: 346 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 1.79-1.89 (m, 1H) 1.98- 
               
               
                   
                 2.11 (m, 1H) 2.11-2.33 (m, 2H) 2.65-2.80 (m, 1H) 3.09-3.21 (m, 1H) 4.02- 
               
               
                   
                 4.16 (m, 2H) 7.02-7.14 (m, 1H) 7.24 (s, 2 H) 7.85-7.97 (m, 1H) 8.04 (d, J = 9.46 
               
               
                   
                 Hz, 3H) 8.33 (d, J = 9.46 Hz, 1H) 
               
               
                   
               
            
           
         
       
     
     Example 5 (Compound 427) 
     2-[6-(Piperidin-4-ylamino)pyridazin-3-yl]-5-(1H-pyrazol-4-yl)phenol tetrahydrochloride 
     Step 1: 3,6-Dibromopyridazine (500 mg, 2.1 mmol), 4-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (970 mg, 2.52 mmol), Pd(dppf)Cl 2  (77 mg, 0.11 mmol), K 2 CO 3  (870 mg, 6.3 mmol) were mixed in a Schlenk tube. The reaction was degassed with N 2  for 15 min and dioxane (8 mL) and water (1 mL) were added and the reaction was heated to 90° C. for 16 h. The reaction was cooled to room temperature, partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , concentrated under vacuum, purified via column chromatography: eluting with gradient hexanes/EtOAc (0% to 40% EtOAc), column: silica 4 g, to provide 3-bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (690 mg, 79%) as an off-white fluffy solid. 
     Step 2: 3-Bromo-6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazine (50 mg, 0.12 mmol), tert-butyl 4-aminopiperidine-1-carboxylate (36 mg, 0.18 mmol), potassium t-butoxide (41 mg, 0.36 mmol), tBuXPhos-Pd-G3 (10 mg, 0.012 mmol) were mixed in a Schlenk tube. The reaction was degassed with Ar then dry THF (2 mL) was added and the reaction was heated to 80° C. for 12 h. The reaction was cooled to room temperature, then partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , concentrated under vacuum, and purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 15% MeOH), column: silica 4 g, to provide tert-butyl 4-((6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazin-3-yl)amino)piperidine-1-carboxylate (45 mg, 70%) as a tan solid. 
     Step 3: A solution of 4-((6-(2-methoxy-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)pyridazin-3-yl)amino)piperidine-1-carboxylate (45 mg, 0.084 mmol) in 2 mL of dry CH 2 Cl 2  was cooled in an ice-water bath. Boron tribromide 1.0 M in CH 2 Cl 2  (0.42 mL, 0.42 mmol) was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with 2 mL of MeOH, stirred for 30 min, then concentrated and purified using preparative HPLC to provide 2-(6-(piperidin-4-ylamino)pyridazin-3-yl)-5-(1H-pyrazol-4-yl)phenol (21 mg, 73%) as a yellowish solid. 
     LC-MS: 377 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 8.95 (s, 2H), 8.25 (d, J=9.6 Hz, 1H), 8.09 (s, 2H), 7.69 (d, J=8.8 Hz, 1H), 7.49-7.41 (m, 1H), 7.21-7.24 (m, 2H), 4.11-4.15 (m, 1H), 3.34-3.39 (m, 4H), 3.01-3.08 (m, 2H), 2.11-2.17 (m, 2H), 1.79 (q, J=9.2 Hz, 2H) 
     Using the procedure described for Example 5 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 426 
                 LC-MS: 351 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9-22-9.28 (m, 2H), 8.34 
               
               
                   
                 (d, J = 9.6 Hz, 1H), 8.06-8.11 (m, 2H), 78.5-7.89 (m, 1H), 7.74 (d, J = 8.2 Hz, 1H), 
               
               
                   
                 7.20-7.27 (m, 2H), 4.67-4.75 (m, 2H), 3.35-3.39 (m, 2H), 3.07-3.09 (m, 2H), 3.05 
               
               
                   
                 (s, 3H), 2.21 (q, J = 10.2 Hz, 2H), 1.83-1.88 (m, 2H) 
               
               
                 432 
                 LC-MS: 338 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.72 (d, J = 9.6 Hz, 1H), 
               
               
                   
                 8.41-8.54 (m, 2H), 7.91-8.08 (m, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.2 Hz, 
               
               
                   
                 1H), 7.38 (s, 1H), 5.51 (quint, J = 2.8 Hz, 1H), 3.30-3.46 (m, 2H), 3.28-3.31 (m, 2H), 
               
               
                   
                 2.33-2.38 (m, 2H), 2.25-2.32 (m, 2H), (3 hydrogens corresponding to OH and NH 
               
               
                   
                 unobserved) 
               
               
                 436 
                 LC-MS: 366 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.17-9.30 (m, 1H), 8.81- 
               
               
                   
                 8.95 (m, 1H), 8.49 (d, J = 9.8 Hz, 1H), 8.17 (s, 2H), 7.94 (d, J = 8.8 Hz, 1H), 7.46 (d, 
               
               
                   
                 J = 9.8 Hz, 1H), 7.18-7.29 (m, 2H), 5.47 (spt, J = 5.7 Hz, 1H), 3.31-3.52 (m, 2H), 2.41 
               
               
                   
                 (dd, J = 12.9, 5.7 Hz, 2H), 1.68 (q, J = 12.0 Hz, 2H), 1.34 (d, J = 6.3 Hz, 6H), (1 
               
               
                   
                 hydrogen corresponding to OH or NH unobserved) 
               
               
                 439 
                 LC-MS: 363 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.07 (s, 2H), 8.28 (d, 
               
               
                   
                 J = 10 Hz, 1H), 1.7 (s, 2H), 7.81 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 9.6 Hz, 1H), 7.19-7.22 
               
               
                   
                 (m, 2H), 3.75-3.81 (m, 4H), 3.58-3.69 (m, 4H), 1.85-1.89 (m, 4H), (1 hydrogen 
               
               
                   
                 corresponding to OH or NH unobserved) 
               
               
                 459 
                 LC-MS: 349 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 10.53 (s, 1H), 10.40 (s, 
               
               
                   
                 1H), 9.79 (br s, 1H), 9.67 (br s, 1H), 8.28 (d, J = 9.6 Hz, 1H), 8.06 (s, 2H), 7.65 (d, 
               
               
                   
                 J = 9.6 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.21-7.25 (m, 1H), 4.53 (q, J = 14 Hz, 2H), 3.64 
               
               
                   
                 (d, J = 12.8 Hz, 1H), 3.52 (d, J = 12.8 Hz, 1H), 3.37-3.40 (m, 2H), 3.15-3.24 (m, 2H), 
               
               
                   
                 1.92-2.02 (m, 2H) 
               
               
                   
               
            
           
         
       
     
     Example 6 (Compound 430) 
     6-[2,3-Difluoro-4-(1H-pyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride 
     Step 1: To a RBF, equipped with a N 2  inlet, were added: 6-bromo-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)pyridazin-3-amine (90 mg, 0.28 mmol), 4-[2,3-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-tetrahydropyran-2-yl-pyrazole (128.8 mg, 0.33 mmol), Pd(PPh 3 ) 4  (31.8 mg, 0.03 mmol), Na 2 CO 3  (87.43 mg, 0.83 mmol). The reaction was degassed with N 2  for 15 min then dioxane (8 mL) and water (2 mL) were added. The reaction was heated to 90° C. for 16 h, then cooled to room temperature, and partitioned between EtOAc and water. The organic layers were dried over Na 2 SO 4 , concentrated on a rotavap, and purified via column chromatography: eluting with gradient CH 2 Cl 2 /MeOH (0% to 30%), column: silica 4 g to provide 6-(2,3-Difluoro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (88 mg, 63%) as a grey solid. 
     Step 2: 6-[2,3-Difluoro-4-(1-tetrahydropyran-2-ylpyrazol-4-yl)phenyl]-N-methyl-N-(2,2,6,6-tetramethyl-4-piperidyl)pyridazin-3-amine (88 mg, 0.17 mmol) was dissolved in MeOH (2 mL) and 4M HCl in dioxane (90 μL, 0.34 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 30 min until LC-MS showed complete consumption of starting material. The reaction mixture was concentrated under reduced pressure to provide 6-(2,3-difluoro-4-(1H-pyrazol-4-yl)phenyl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride salt. 
     LC-MS: 427 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.21-9.33 (m, 1H), 8.27-8.43 (m, 1H), 8.20 (s, 2H), 8.01 (d, J=9.8 Hz, 1H), 7.60-7.79 (m, 3H), 5.01-5.14 (m, 1H), 3.05 (s, 3H), 2.10 (td, J=13.2, 1.6 Hz, 2H), 1.79 (dd, J=12.9, 4.1 Hz, 2H), 1.55 (s, 6H), 1.50 (s, 6H) 
     Using the procedure described for Example 6 above, additional compounds described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 426 
                 LC-MS: 427 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.22-9.38 (m, 1H), 8.33- 
               
               
                   
                 8.45 (m, 1H), 8.21 (d, J = 1.9 Hz, 2H), 7.97 (dd, J = 10.4, 2.8 Hz, 1H), 7.86 (d, J = 5.7 
               
               
                   
                 Hz, 1H), 7.81 (dd, J = 11.7, 6.6 Hz, 1H), 7.54-7.63 (m, 1H), 5.09-5.16 (m, 1H), 3.03 
               
               
                   
                 (s, 3H), 2.09 (t, J = 12.9 Hz, 2H), 1.78 (dd, J = 12.9, 3.8 Hz, 2H), 1.55 (s, 6H), 1.51 (s, 
               
               
                   
                 6H) 
               
               
                 431 
                 LC-MS: 414 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.24-9.35 (m, 1H), 8.43- 
               
               
                   
                 8.58 (m, 1H), 8.22 (d, J = 1.6 Hz, 2H), 8.06 (dd, J = 9.1, 1.9 Hz, 1H), 7.87 (dd, J = 12.1, 
               
               
                   
                 6.5 Hz, 1H), 7.83 (dd, J = 11.5, 6.5 Hz, 1H), 7.37 (d, J = 9.5 Hz, 1H), 5.77 (tt, J = 10.7, 
               
               
                   
                 4.1 Hz, 1H), 2.33 (dd, J = 13.1, 3.9 Hz, 2H), 1.84 (dd, J = 12.9, 11.3 Hz, 2H), 1.54 (s, 
               
               
                   
                 6H), 1.52 (s, 6H) 
               
               
                 435 
                 LC-MS: 378 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.57-8.58 (m, 1H), 8.55 
               
               
                   
                 (d, J = 5.0 Hz, 1H), 8.45 (s, 2H), 8.05-8.10 (m, 1H), 7.95-7.99 (m, 1H), 7.86 (s, 1H), 
               
               
                   
                 7.82 (d, J = 9.5 Hz, 1H), 5.79 (tt, J = 10.4, 4.4 Hz, 1H), 2.53 (dd, J = 14.5, 4.5 Hz, 2H), 
               
               
                   
                 1.86-2.01 (m, 2H), 1.66 (s, 6H), 1.60 (s, 6H), (2 hydrogens corresponding to NH 
               
               
                   
                 unobserved) 
               
               
                 437 
                 LC-MS: 396 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.28-9.44 (m, 1H), 8.47- 
               
               
                   
                 8.61 (m, 1H), 8.25 (s, 2H), 8.01 (dd, J = 9.3, 2.0 Hz, 1H), 7.92 (t, J = 8.2 Hz, 1H), 7.69 
               
               
                   
                 (dd, J = 12.8, 1.7 Hz, 1H), 7.65 (dd, J = 8.0, 1.7 Hz, 1H), 7.34 (d, J = 9.1 Hz, 1H), 5.76 
               
               
                   
                 (tt, J = 10.7, 4.1 Hz, 1H), 2.33 (dd, J = 13.2, 3.9 Hz, 2H), 1.85 (dd, J = 13.2, 10.1 Hz, 
               
               
                   
                 2H), 1.54 (s, 6H), 1.53 (s, 6H) 
               
               
                 440 
                 LC-MS: 359 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: .06 (d, J = 10.1 Hz, 1H), 
               
               
                   
                 7.78 (dd, J = 9.5, 6.3 Hz, 1H), 7.32 (d, J = 9.8 Hz, 1H), 6.58-6.76 (m, 2H), 5.11 (tt, 
               
               
                   
                 J = 12.0, 4.1 Hz, 1H), 3.02 (s, 3H), 1.73 (dd, J = 12.9, 3.5 Hz, 2H), 1.63 (t, J = 12.5 Hz, 
               
               
                   
                 2H), 1.43 (s, 6H), 1.27 (s, 6H), (1 hydrogen corresponding to NH unobserved) 
               
               
                 441 
                 LC-MS: 364 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 1.33 (d, J = 6.62 Hz, 6H) 
               
               
                   
                 1.65 (q, J = 12.40 Hz, 2H) 2.42 (d, J = 12.61 Hz, 2H) 3.38-3.50 (m, 2H) 5.48 (s, 1H) 
               
               
                   
                 6.51-6.63 (m, 1H) 7.42-7.57 (m, 3H) 7.80 (d, J = 1.58 Hz, 1H) 8.09 (d, J = 8.83 Hz, 
               
               
                   
                 1H) 8.50 (d, J = 9.46 Hz, 1H) 8.61 (d, J = 2.52 Hz, 1H) 8.76 (br s., 1H) 9.12 (br s., 1H) 
               
               
                   
                 13.18 (s, 1H) 
               
               
                 442 
                 LC-MS: 379 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 8.42 (s, 1H), 8.28 (dd, 
               
               
                   
                 J = 1.6, 0.9 Hz, 1H), 8.03 (dd, J = 9.1, 1.6 Hz, 1H), 7.95 (s, 1H), 7.67 (d, J = 9.1 Hz, 
               
               
                   
                 1H), 7.14 (d, J = 9.1 Hz, 1H), 5.03-5.17 (m, 1H), 4.19 (s, 3H), 2.94 (s, 3H), 1.49-1.58 
               
               
                   
                 (m, 2H), 1.37-1.48 (m, 2H), 1.27 (s, 6H), 1.10 (s, 6H), (1 hydrogen corresponding to 
               
               
                   
                 NH unobserved) 
               
               
                 443 
                 LC-MS: 366 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.35 (s, 1H), 8.31 (dd, 
               
               
                   
                 J = 1.6, 0.9 Hz, 1H), 8.11 (d, J = 9.1 Hz, 1H), 7.99 (dd, J = 9.1, 1.9 Hz, 1H), 7.75 (dt, 
               
               
                   
                 J = 9.1, 0.9 Hz, 1H), 7.21 (d, J = 9.5 Hz, 1H), 5.81 (tt, J = 11.2, 4.1 Hz, 1H), 4.27 (s, 
               
               
                   
                 3H), 2.28 (dd, J = 12.6, 4.1 Hz, 2H), 1.48 (t, J = 12.3 Hz, 2H), 1.41 (s, 6H), 1.30 (s, 
               
               
                   
                 6H), (1 hydrogen corresponding to NH unobserved) 
               
               
                 445 
                 LC-MS: 379 [M + H] + .  1 H NMR (500 MHz, acetone-d 6 ) δ: 8.52 (dt, J = 7.0, 1.1 Hz, 
               
               
                   
                 1H), 8.13 (dt, J = 8.8, 1.3 Hz, 1H), 7.66 (d, J = 9.8 Hz, 1H), 7.28 (ddd, J = 9.0, 6.8, 1.3 
               
               
                   
                 Hz, 1H), 7.13 (d, J = 9.5 Hz, 1H), 6.89 (td, J = 6.9, 1.4 Hz, 1H), 5.22 (tt, J = 12.3, 3.5 
               
               
                   
                 Hz, 1H), 3.04 (s, 3H), 2.63 (s, 3H), 1.67 (dd, J = 12.3, 3.5 Hz, 2H), 1.56 (t, J = 12.3 
               
               
                   
                 Hz, 2H), 1.36 (s, 6H), 1.18 (s, 6H), (1 hydrogen corresponding to NH unobserved) 
               
               
                 446 
                 LC-MS: 352 [M + H] + .  1 H NMR (500 MHz, acetone-d 6 ) δ: 9.14 (dd, J = 1.6, 0.9 Hz, 
               
               
                   
                 1H), 7.98 (dd, J = 9.5, 1.9 Hz, 1H), 7.94 (t, J = 0.9 Hz, 1H), 7.89 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 7.63 (dt, J = 9.5, 0.8 Hz, 1H), 7.60 (d, J = 1.3 Hz, 1H), 7.14 (d, J = 9.5 Hz, 1H), 5.34 (tt, 
               
               
                   
                 J = 12.6, 3.5 Hz, 1H), 1.67 (dd, J = 12.3, 3.8 Hz, 2H), 1.55 (t, J = 12.1 Hz, 2H), 1.36 (s, 
               
               
                   
                 6H), 1.17 (s, 6H), (1 hydrogen corresponding to NH unobserved) 
               
               
                 447 
                 LC-MS: 394 [M + H] + .  1 H NMR (500 MHz, acetone-d 6 ) δ: 8.47 (d, J = 2.5 Hz, 1H), 
               
               
                   
                 8.05 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 1.9 Hz, 1H), 7.70 (d, 
               
               
                   
                 J = 2.2 Hz, 1H), 7.59 (dd, J = 8.5, 2.2 Hz, 1H), 7.06 (d, J = 9.1 Hz, 1H), 6.57 (dd, 
               
               
                   
                 J = 2.4, 1.7 Hz, 1H), 5.85 (tt, J = 11.3, 4.1 Hz, 1H), 2.21 (dd, J = 12.1, 3.9 Hz, 2H), 
               
               
                   
                 2.04-2.08 (m, 2H), 1.35 (s, 6H), 1.18 (s, 6H), (2 hydrogens corresponding to OH 
               
               
                   
                 and NH unobserved) 
               
               
                 452 
                 LC-MS: 409 [M + H] + .  1 H NMR (500 MHz, acetone-d 6 ) δ: 7.59 (dd, J = 8.5, 6.0 Hz, 
               
               
                   
                 1H), 7.46 (s, 2H), 7.31 (dd, J = 10.1, 2.5 Hz, 1H), 7.15 (td, J = 8.5, 2.5 Hz, 1H), 7.04 
               
               
                   
                 (d, J = 9.5 Hz, 1H), 6.91 (d, J = 9.5 Hz, 1H), 5.23 (tt, J = 12.3, 2.8 Hz, 1H), 3.00 (s, 
               
               
                   
                 3H), 1.65 (dd, J = 12.3, 3.5 Hz, 2H), 1.51 (t, J = 12.1 Hz, 2H), 1.33 (s, 6H), 1.15 (s, 
               
               
                   
                 6H), (2 hydrogens corresponding to NH unobserved) 
               
               
                 455 
                 LC-MS: 344 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.17 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 7.66 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 9.5 Hz, 1H), 6.44 (dd, J = 8.7, 2.4 Hz, 1H), 6.41 
               
               
                   
                 (d, J = 2.5 Hz, 1H), 5.71 (tt, J = 11.0, 3.8 Hz, 1H), 2.23 (dd, J = 12.6, 4.1 Hz, 2H), 1.40- 
               
               
                   
                 1.47 (m, 2H), 1.39 (s, 6H), 1.27 (s, 6H), (3 hydrogens corresponding to OH and NH 
               
               
                   
                 unobserved) 
               
               
                 456 
                 LC-MS: 425 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 9.23-9.39 (m, 1H), 8.39- 
               
               
                   
                 8.52 (m, 1H), 8.26 (s, 2H), 8.00-8.08 (m, 1H), 7.93 (s, 1H), 7.81-7.85 (m, 1H), 7.78 
               
               
                   
                 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 8.2 Hz, 1H), 4.95-5.03 (m, 1H), 3.08 (s, 3H), 2.13 (t, 
               
               
                   
                 J = 12.9 Hz, 2H), 1.81 (dd, J = 12.9, 3.5 Hz, 2H), 1.56 (s, 6H), 1.52 (s, 6H) 
               
               
                 458 
                 LC-MS: 414 [M + H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 8.70-9.36 (m, 1H), 8.29 (s, 
               
               
                   
                 2H), 7.85 (d, J = 9.1 Hz, 1H), 7.60 (d, J = 9.5 Hz, 1H), 7.33-7.39 (m, 1H), 5.59-5.68 
               
               
                   
                 (m, 1H), 2.24-2.33 (m, 2H), 1.72-1.82 (m, 2H), 1.50 (s, 6H), 1.48 (s, 6H), (2 
               
               
                   
                 hydrogens corresponding to NH unobserved) 
               
               
                   
               
            
           
         
       
     
     Example 7 (Compound 434) 
     6-[2-Methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl]-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine hydrochloride 
     6-(2-Methoxy-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (6 mg) was dissolved in 1 mL of 4N HCl/dioxane and the resulting mixture was stirred at RT for 20 minutes. The mixture was evaporated and triturated with ether to provide 6-(2-methoxy-6-(1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine 4 mg, 75%). 
     LC-MS: 422 [M+H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.42-8.47 (m, 1H), 8.33-8.42 (m, 2H), 8.09-8.17 (m, 1H), 7.99-8.08 (m, 1H), 7.50-7.56 (m, 1H), 5.0 (m, 1H), 4.16 (s, 3H), 3.20 (s, 3H), 1.94-2.15 (m, 4H), 1.65 (s, 6H), 1.57 (s, 6H) 
     Example 8 (Compound 460) 
     3-{6-[Methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyridazin-3-yl}-6-(1H-pyrazol-4-yl)pyridin-2-ol hydrochloride 
     Step 1: 6-Chloro-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (280 mg, 1.0 mmol) was dissolved in 10 mL, a mixture of dioxane and water (4:1). To the solution was added sodium carbonate (190 mg, 3 eq), (6-chloro-2-methoxypyridin-3-yl)boronic acid (190 mg, 1 eq) and Pd(Ph 3 P) 4  (70 mg, 0.1 eq). The reaction mixture was stirred at 90° C. for 16 h, then applied to a column and purified using DCM/MeOH to yield (133 mg, 55%) 6-(6-chloro-2-methoxypyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine. 
     LC-MS: 390 [M+H] + .  1 H NMR (500 MHz, DMSO-d 6 ) δ: 8.25 (d, J=7.88 Hz, 1H), 7.83 (d, J=9.77 Hz, 1H), 7.24 (d, J=7.88 Hz, 1H), 7.11 (d, J=9.77 Hz, 1H), 5.00-5.24 (m, 1H), 3.93 (s, 3H), 2.87-2.96 (m, 3H), 1.40-1.57 (m, 4H), 1.21-1.29 (m, 7H), 1.10 (br s, 6H 
     Step 2: 6-(6-Chloro-2-methoxypyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (90 mg) was dissolved in a mixture of dioxane and water (4:1, 5 mL). To the solution was added sodium carbonate (100 mg, 3 eq), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (70 mg, 1.1 eq) and Pd(Ph 3 P) 4  (27 mg, 0.1 eq). The reaction mixture was stirred at 90° C. for 16 h, then purified by column chromatography using DCM/MeOH to yield 80 mg (68%) of 6-(2-methoxy-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine. 
     Step 3: 6-(2-Methoxy-6-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-3-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)pyridazin-3-amine (45 mg) was dissolved in 4 mL of 4N HCl/dioxane and the resulting mixture was heated for 2 hours at 60° CF. The resulting mixture was evaporated and triturated with ether to provide 3-(6-(methyl(2,2,6,6-tetramethylpiperidin-4-yl)amino)pyridazin-3-yl)-6-(1H-pyrazol-4-yl)pyridin-2-ol (24 mg, 61%). 
     LC-MS: 408 [M+H] + ; NMR (500 MHz, methanol-d 4 ) δ: 8.62-8.69 (m, 1H), 8.55-8.61 (m, 1H), 8.39 (s, 2H), 7.95-8.06 (m, 1H), 7.04-7.14 (m, 1H), 5.02-5.24 (m, 1H), 3.18 (s, 3H), 2.03 (s, 4H), 1.67 (s, 6H), 1.57 (s, 6H) 
     Using the procedure described for Example 8 above, an additional compound described herein may be prepared by substituting the appropriate starting materials reagents, and reaction conditions, obtaining compounds such as those selected from: 
     
       
         
           
               
               
             
               
                   
               
               
                 Cpd 
                 Data 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 461 
                 LC-MS: 395 [M + H] + .  1 H NMR (500 MHz, methanol-d 4 ) δ: 8.46 (d, J = 9.5 Hz, 1H), 
               
               
                   
                 8.33-8.42 (m, 1H), 8.29 (d, J = 7.6 Hz, 1H), 8.10-8.23 (m, 1H), 7.20 (d, J = 9.1 Hz, 
               
               
                   
                 1H), 6.86 (d, J = 7.3 Hz, 1H), 5.84 (tt, J = 10.4, 3.8 Hz, 1H), 2.49 (dd, J = 13.9, 4.1 Hz, 
               
               
                   
                 2H), 1.86 (dd, J = 13.9, 10.4 Hz, 2H), 1.65 (s, 6H), 1.56 (s, 6H), (3 hydrogens 
               
               
                   
                 corresponding to OH and NH unobserved) 
               
               
                   
               
            
           
         
       
     
     BIOLOGICAL EXAMPLES 
     The following in vitro biological examples demonstrate the usefulness of the compounds of the present description for treating Huntington&#39;s disease. 
     To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed. 
     Example 1 
     Development and Validation of Meso Scale Discovery (MSD) Assay to Quantify Mutant and Total Huntingtin Protein (HTT)—Best Pair Analysis for Endogenous HTT Detection 
     To identify orally bioavailable small molecules useful for HTT reduction, high throughput ELISA methods to detect and measure both total HTT (wild-type and mutant) (tHTT) and mutant HTT (mHTT) in cells and tissues from HD patients and animal models are needed. The method described herein permits relatively high throughput protein measurement of tHTT and mHTT levels in cells and tissues from HD patients and in HD animal models. The ELISA method described herein enables screening of molecules for their ability to decrease the level of HTT and to identify and optimize small molecules for use in treating HD. 
     To determine the combination of antibodies that detect HTT (wild type and mutant) in a sensitive, high throughput format, multiple commercially available antibodies (Table 1) were screened in capture/detection combinations. 
     Protocol for Best Pair Analysis for Antibody Comparison in Detecting Total and Mutant HTT in Cells 
     
         
         1. Cells were cultured in a cell culture-compatible 96-well plate. 
         2. The medium was removed and 50-100 μL of lysis buffer per well (composition described below) was added to cells to provide a “cell lysate”. The plate was placed on a shaker at 4° C. for 30 minutes, then stored at −20° C. 
         3. A Capture Antibody Diluent was prepared by diluting the capture antibody in PBS for standard plates as described in the plate layout, then 30 μL of the Capture Antibody Diluent was added per well. The plate was sealed and incubated at 4° C. overnight. 
         4. The plate was washed 3× with 200 μL of Wash Buffer. Blocking Buffer (150 μL per well) was added, then the plate was sealed and incubated on a plate shaker for 3-4 hours at room temperature (RT). 
         5. The Blocking Buffer was decanted and the plate was washed 3× with 200 μL of Wash Buffer. The cell lysate (25 μL per well) was then added. The plate was sealed and incubated at 4° C. overnight. 
         6. A First Detection Antibody Diluent was prepared by diluting a first detection antibody for pairing in an Assay Antibody Diluent. The plate was washed 3× with 200 μL of Wash Buffer, then 25 μL of the First Detection Antibody Diluent was added per well. The plate was sealed and incubated on a plate shaker for 1 hour at RT. 
         7. A Second Detection Antibody Diluent was prepared by diluting a second detection antibody for pairing in an Assay Antibody Diluent. The plate was washed 3× with 200 μL of Wash Buffer, then 25 μL of the Second Detection Antibody Diluent was added per well. The plate was sealed and incubated on a plate shaker for 1 hour at RT. 
         8. The Read Buffer was diluted 4×. The plate was washed 3× with 200 μL of Wash Buffer, then 150 μL of the Read Buffer was added per well. The plate were read immediately following. 
       
    
     The various commercially available antibodies screened in the Best Pair Analysis, providing different capture/detection combinations are shown in Table 1. The capture/detection antibody pairs evaluated are shown in Table 2. The two antibody pairs that gave the maximum spread of values (higher signal to noise ratio) were selected for polyglutamine-expanded (mHTT) and total human HTT detection. 
     
       
         
           
               
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Species 
                 ID 
                 Antibody Epitope 
               
               
                   
               
             
            
               
                 monoclonal 
                 MAB2166 
                 Huntingtin fragment from aa 181-810 as a fusion protein 
               
               
                 mouse 
                   
                   
               
               
                 monoclonal rat 
                 MAB2174 
                 Huntingtin fusion protein 549-679, fused to Glutathione S- 
               
               
                   
                   
                 tranferase 
               
               
                 monoclonal 
                 MAB5374 
                 GST fusion protein from the first 256 amino acids from human 
               
               
                 mouse 
                   
                 huntingtin with the deletion of the polyglutamine tract 
               
               
                 goat polyclonal 
                 sc-8767 
                 Peptide mapping near the N-terminus of Huntingtin of human 
               
               
                   
                   
                 origin (N18) 
               
               
                 monoclonal 
                 P1874 
                 GST human Huntingtin (N-terminal fragment of 171 amino 
               
               
                 mouse 
                   
                 acids containing 65Q) 
               
               
                 monoclonal 
                 MAB1574 
                 Homopolymeric glutamine stretch 
               
               
                 mouse 
                   
                   
               
               
                 monoclonal 
                 #5656S 
                 Synthetic peptide corresponding to residues surrounding 
               
               
                 rabbit 
                   
                 Pro1220 of human huntingtin protein 
               
               
                 monoclonal 
                 MW1 
                 DRPLA-19Q 
               
               
                 mouse 
               
               
                   
               
            
           
         
       
     
     
       
         
           
               
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                   
                   
                 Signal to 
               
               
                 Pair 
                 HTT MSD 
                 ID 
                 Noise ratio 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Capture/Detection 
                 Total 
                 MAB2166/MAB2174 
                 95 
               
               
                 Capture/Detection 
                 Total 
                 MAB2166/sc-8767 
                 6 
               
               
                 Capture/Detection 
                 Total 
                 sc-8767/#5656 
                 5 
               
               
                 Capture/Detection 
                 Total 
                 MAB2166/#5656S 
                 483 
               
               
                 Capture/Detection 
                 Mutant 
                 MAB5374/#5656S 
                 8 
               
               
                 Capture/Detection 
                 Mutant 
                 MAB1574/#5656S 
                 25 
               
               
                 Capture/Detection 
                 Mutant 
                 P1874/#5656S 
                 20 
               
               
                 Capture/Detection 
                 Mutant 
                 MW1/#5656S 
                 45 
               
               
                   
               
            
           
         
       
     
     Characteristics for Best Pair capture/detection antibody pairs are those combinations that give minimum background and maximum signal. Such highly sensitive ELISA assays would be useful to detect HTT in the context of drug discovery for screening agents (small and large molecules and gene therapies) and for use in detecting HTT as a biomarker in clinical studies. Such capture/detection antibody pairs for quantifying total HTT are selected from MAB2166/MAB2174 and MAB2166/#5656S. Such capture/detection antibody pairs for quantifying mutant HTT are selected from MAB1574/#5656S, P1874/#5656S and MW1/#5656S. The antibody pair for mHTT (MW  1 /#5656S) and the other for total HTT (MAB2166/#5656S) from this analysis were further optimized and validated to provide high-throughput assays that enabled HTT detection in patient fibroblasts and lymphocytes. 
     The Endogenous Huntingtin Protein assay used in Example 2 was developed using the Best Pair antibodies identified in Table 2, providing highly sensitive, high-throughput detection assays for polyglutamine-expanded (mHTT) and total human HTT in multiple cell systems. The platform used for the assay is the ELISA-based Meso Scale Discovery (MSD) electrochemiluminescence assay platform. 
     Example 2 
     Endogenous Huntingtin Protein Assay 
     Meso Scale Discovery (MSD) 96-well or 384-well plates were coated overnight at 4° C. with MW1 (expanded polyglutamine) or MAB2166 monoclonal antibody (for capture) at a concentration of 1 μg/mL in PBS (30 μL per well). Plates were then washed three times with 300 μL wash buffer (0.05% Tween-20 in PBS) and blocked (100 μL blocking buffer; 5% BSA in PBS) for 4-5 hours at room temperature with rotational shaking and then washed three times with wash buffer. 
     Samples (25 μL) were transferred to the antibody-coated MSD plate and incubated overnight at 4° C. After removal of the lysates, the plate was washed three times with wash buffer, and 25 μL of #5656S (Cell signaling; rabbit monoclonal) secondary antibody (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 Hour at room temperature. Following incubation with the secondary antibody, the wells were rinsed with wash buffer after which 25 μL of goat anti-rabbit SULFO TAG secondary detection antibody (required aspect of the MSD system) (diluted to 0.25 μg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 hour at room temperature. After rinsing three times with wash buffer, 150 μL of read buffer T with surfactant (MSD) were added to each empty well, and the plate was imaged on a SI 6000 imager (MSD) according to manufacturers&#39; instructions provided for 96- or 384-well plates. The resulting IC 50  values (μM) for compounds tested are shown in Table 3. 
     As shown in Table 3, test compounds described herein had the following IC 50  values, an IC 50  value between &gt;3 μM and ≤9 μM is indicated by a single star (*), an IC 50  value between &gt;1 μM and ≤3 μM is indicated by two stars (**), an IC 50  value between &gt;0.5 μM and ≤1 μM is indicated by three stars (***), an IC 50  value between &gt;0.1 μM and ≤0.5 μM is indicated by four stars (****) and an IC 50  value of ≤0.1 μM is indicated by five stars (*****). 
     
       
         
           
               
               
               
             
               
                 TABLE 3 
               
               
                   
               
               
                   
                 Cpd 
                 IC 50   
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                   
                 16 
                 * 
               
               
                   
                 26 
                 **** 
               
               
                   
                 31 
                 **** 
               
               
                   
                 460 
                 * 
               
               
                   
                 39 
                 * 
               
               
                   
                 44 
                 ***** 
               
               
                   
                 46 
                 ***** 
               
               
                   
                 47 
                 **** 
               
               
                   
                 48 
                 ***** 
               
               
                   
                 51 
                 ***** 
               
               
                   
                 63 
                 ***** 
               
               
                   
                 64 
                 ***** 
               
               
                   
                 170 
                 ***** 
               
               
                   
                 176 
                 ***** 
               
               
                   
                 200 
                 ***** 
               
               
                   
                 207 
                 **** 
               
               
                   
                 212 
                 ***** 
               
               
                   
                 218 
                 ***** 
               
               
                   
                 258 
                 **** 
               
               
                   
                 307 
                 **** 
               
               
                   
                 315 
                 ***** 
               
               
                   
                 318 
                 ***** 
               
               
                   
                 348 
                 ***** 
               
               
                   
                 350 
                 ***** 
               
               
                   
                 352 
                 **** 
               
               
                   
                 393 
                 ***** 
               
               
                   
                 411 
                 ***** 
               
               
                   
                 412 
                 ***** 
               
               
                   
                 413 
                 ***** 
               
               
                   
                 414 
                 ***** 
               
               
                   
                 415 
                 ***** 
               
               
                   
                 416 
                 ***** 
               
               
                   
                 417 
                 ***** 
               
               
                   
                 418 
                 ***** 
               
               
                   
                 419 
                 ***** 
               
               
                   
                 420 
                 ***** 
               
               
                   
                 421 
                 ***** 
               
               
                   
                 422 
                 ***** 
               
               
                   
                 423 
                 ***** 
               
               
                   
                 424 
                 **** 
               
               
                   
                 425 
                 **** 
               
               
                   
                 426 
                 **** 
               
               
                   
                 427 
                 **** 
               
               
                   
                 428 
                 **** 
               
               
                   
                 429 
                 **** 
               
               
                   
                 430 
                 **** 
               
               
                   
                 431 
                 **** 
               
               
                   
                 432 
                 **** 
               
               
                   
                 433 
                 **** 
               
               
                   
                 434 
                 *** 
               
               
                   
                 435 
                 *** 
               
               
                   
                 436 
                 *** 
               
               
                   
                 437 
                 ** 
               
               
                   
                 438 
                 ** 
               
               
                   
                 439 
                 ** 
               
               
                   
                 440 
                 * 
               
               
                   
                 441 
                 * 
               
               
                   
                 442 
                 * 
               
               
                   
                 443 
                 * 
               
               
                   
                 444 
                 * 
               
               
                   
                 445 
                 * 
               
               
                   
                 446 
                 * 
               
               
                   
                 447 
                 * 
               
               
                   
                 448 
                 * 
               
               
                   
                 449 
                 * 
               
               
                   
                 450 
                 * 
               
               
                   
                 451 
                 * 
               
               
                   
                 451 
                 * 
               
               
                   
                 452 
                 * 
               
               
                   
                 454 
                 * 
               
               
                   
                 455 
                 * 
               
               
                   
                 456 
                 * 
               
               
                   
                 456 
                 * 
               
               
                   
                 456 
                 * 
               
               
                   
                 457 
                 * 
               
               
                   
                 458 
                 * 
               
               
                   
                 459 
                 * 
               
               
                   
                 460 
                 * 
               
               
                   
                 461 
                 * 
               
               
                   
                 462 
                 * 
               
               
                   
                 463 
                 * 
               
               
                   
                 464 
                 * 
               
               
                   
                 465 
                 * 
               
               
                   
               
            
           
         
       
     
     Without regard to whether a document cited herein was specifically and individually indicated as being incorporated by reference, all documents referred to herein are incorporated by reference into the present application for any and all purposes to the same extent as if each individual reference was fully set forth herein. 
     Having now fully described the subject matter of the claims, it will be understood by those having ordinary skill in the art that the same can be performed within a wide range of equivalents without affecting the scope of the subject matter or embodiments described herein. It is intended that the appended claims be interpreted to include all such equivalents.